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ABSTRACT  
   
Studies have demonstrated that anthocyanins can function as antioxidants, 
reduce inflammation, and improve dyslipidemia. Tart cherries are anthocyanin-
rich, making them particularly attractive as a functional food to improve 
cardiovascular disease (CVD) risk. There have been few published studies to date 
examining the impact of tart cherries on biomarkers of dyslipidemia and 
inflammation, particularly in overweight and obese individuals at high risk for 
these conditions. This study evaluated the effect of consuming 100% tart cherry 
juice daily on blood lipids including total cholesterol, low-density lipoprotein 
cholesterol (LDL-C), calculated very low density lipoprotein cholesterol (VLDL-
C), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), and the 
CVD risk ratios, as well as the inflammatory biomarkers interleukin 6 (IL-6), 
interleukin 10 (IL-10), tumor necrosis factor-alpha (TNF-α), C-reactive protein 
(CRP), monocyte chemotactic protein-1 (MCP-1), and erythrocyte sedimentation 
rate (ESR) following a 4-week period. Based on the high anthocyanin content of 
tart cherries, it was hypothesized that the lipid and inflammatory profiles would 
be significantly improved following the intervention. A total of 26 men and 
women completed this 4-week randomized, single-blind, placebo-controlled, 
crossover study. Participants were randomized to drink either 8 ounces of placebo 
beverage or tart cherry juice daily for 4 weeks. Following a 4-week washout 
period, the alternate beverage was consumed. Ultimately, this investigation 
demonstrated no statistically significant alterations in any of the lipid or 
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inflammatory biomarkers when analyzed across time and between interventions 
(p > 0.05). As expected, glucose and insulin parameters remained stable over the 
duration of the study, as well as self-reported physical activity level, total calorie 
consumption, and macronutrient intake. However, trans-fat was reported to be 
significantly higher during the cherry arm of the study as compared to the placebo 
arm (p < 0.05), potentially confounding other results. Although the results of this 
study were equivocal, it is feasible that a higher dose, longer treatment duration, 
or more susceptible target population may be required to elicit significant effects. 
Consequently, further investigation is necessary to clarify this research. 
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Chapter 1 
Introduction 
Cardiovascular disease (CVD), obesity, and diabetes are chronic 
conditions associated with low-grade inflammation and oxidative damage to cells 
and their constituents (1). Diet has the potential to mediate these effects. Several 
epidemiological studies have demonstrated a protective effect by fruits and 
vegetables against the development of chronic diseases, and it has been suggested 
that plant compounds called polyphenols are largely responsible for this effect. (2-
4). As major antioxidants in our diet, polyphenols function to protect cells against 
oxidative damage by up-regulating the expression of certain antioxidant and 
detoxifying enzymes (5) and by scavenging free radicals and chelating metals (6). 
Studies also show that polyphenols may protect against CVD by inhibiting the 
oxidation of low-density lipoprotein (LDL) associated with the development of 
atherosclerosis, improving endothelial function by inducing vasorelaxation, 
inhibiting platelet aggregation, and functioning as an anti-thrombotic agent (1). 
Polyphenols have also been shown to exert anti-inflammatory effects (7). 
 Anthocyanins are one of the major classes of polyphenols that exhibit a 
wide range of biological activities. They are water-soluble pigments that give fruit 
and vegetables their red, purple, and blue colors, and primary sources include 
blueberries, raspberries, black currants, purple grapes, strawberries, and cherries 
(6). Because of their high anthocyanin content, many studies on anthocyanin 
activity have been done using tart cherries as a source. Such studies have 
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demonstrated that anthocyanins within this fruit have antioxidant activity greater 
than alpha-tocopherol (8, 9) and display activity comparable to the commercial 
antioxidants butylated hydroxyanisole (BHA) and butylated hydroxytoluene 
(BHT) (6)(9). A study conducted by Saric et al. (10) in mice showed that the 
consumption of tart cherry juice exerted an antioxidant effect through increased 
activity of superoxide dismutase (SOD) and glutathione peroxidase (Gpx). An 
improved antioxidant effect has also been shown in humans in a study completed 
by Traustadottir et al. (11) where tart cherry juice increased the capacity of older 
adults to resist oxidative damage following an acute oxidative challenge. 
 There are limited studies to support that anthocyanins from cherries may 
protect against dyslipidemia. In a study conducted by Seymour et al. (12), Dahl-
SS rats fed a tart cherry-enriched diet exhibited significantly reduced total 
cholesterol and triglycerides compared to the control diet (75 compared to 87 
mg/dL total cholesterol, and 28 compared to 34 mg/dL triglycerides, 
respectively).  In a more recent study by Seymour et al. (13), Zucker fatty rats fed 
tart cherry powder demonstrated a similar reduction in lipid values when 
compared to those fed a control diet (185 compared to 207 mg/dL total 
cholesterol, and 284 compared to 241 mg/dL triglycerides, respectively). 
Although several studies have shown cherry consumption to have a beneficial 
effect on lipid levels in rats, a study completed by Kelley et al. (14) in humans 
failed to duplicate these results. In this study, total cholesterol, LDL-cholesterol, 
high-density lipoprotein (HDL) cholesterol, and triglyceride levels were measured 
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in healthy men and women and were not affected by the consumption of Bing 
sweet cherries. 
 While relatively few studies have examined the effect of a cherry 
intervention on serum lipid levels in both human and animal models, a larger 
number of studies have been conducted with the purpose of measuring alterations 
in inflammatory markers. Obesity greatly contributes to the inflammatory process, 
as an overabundance of white adipose tissue (WAT) increases the production and 
secretion of several inflammatory cytokines, including interleukin-6 (IL-6) and 
tumor necrosis factor-alpha (TNF-α) (15). C-reactive protein (CRP) is an 
inflammatory marker that is a predictive factor for coronary heart disease, and its 
levels are directly related to Il-6 production. In the study by Kelley et al. (14) an 
inverse relationship was demonstrated between the human consumption of Bing 
sweet cherries for a 28-day period and serum CRP. In the study by Seymour et al. 
(13) Zucker rats experienced a 14% increase in lean body mass and an 18% 
decrease in fat mass after consuming cherry powder for 12 weeks, and also 
demonstrated a significant decrease in retroperitoneal (abdominal) and plasma IL-
6 and TNF-α expression. Additional studies have shown cherries to modulate 
inflammatory pathways by inhibiting cyclooxygenase (COX) 1 and 2 enzymes 
(16). Non-steroidal anti-inflammatory drugs such as aspirin function by 
irreversibly inhibiting the activity of the COX enzymes (7), and one in vitro study 
showed anthocyanins to have greater anti-inflammatory activity than aspirin (9).  
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 There have been many studies evaluating and substantiating the role of tart 
cherries as a potent antioxidant source. However, studies exploring the ability of 
tart cherries to lower serum lipid values and markers of inflammation have 
reported conflicting outcomes. There is some evidence that tart cherries have 
lipid-lowering capacity, but results derived from such studies have generally used 
rodent models and may therefore be less relevant to humans. There have been 
some promising studies conducted on the ability of cherries to lower markers of 
inflammation, but additional well-controlled research studies in humans are 
necessary. It would be beneficial to recruit participants possessing elevated 
baseline plasma lipid values and inflammatory markers since this study 
population is more prone to develop CVD and may be more likely to respond to a 
dietary intervention. Overweight or obese individuals have a greater potential to 
exhibit dyslipidemia and/or inflammation. Very few studies demonstrating the 
effects of tart cherry supplementation on lipid values and inflammatory markers 
within an overweight or obese population have been published. 
Purpose  
The purpose of this randomized, crossover, single blinded, placebo-
controlled study was to examine the effects of tart cherry juice consumption on 
serum lipids (total cholesterol, triglycerides, LDL-C, calculated VLDL-C, HDL-
C) and inflammatory markers (ESR, MCP-1, IL-6, TNF-α, hsCRP, and IL-10) in 
overweight and obese subjects from the greater Phoenix region. 
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Hypotheses and Aims 
• Hypothesis:  
Daily consumption of 100% tart cherry juice will improve biomarkers of 
dyslipidemia and inflammation without disrupting glucose homeostasis. 
• Specific Aim 1: 
To determine whether daily tart cherry consumption will improve 
biomarkers of dyslipidemia (total cholesterol, triglycerides, LDL-C, 
calculated VLDL-C, HDL-C, and calculated CVD risk ratios) without 
altering glucose homeostasis in overweight and obese individuals. 
• Specific Aim 2: 
To determine whether daily tart cherry consumption will affect biomarkers 
of inflammation (ESR, hsCRP, TNF-alpha, IL-6, MCP-1, IL-10). 
Definition of Terms 
Overweight: Overweight is defined as having a BMI between 25.0 kg/m2 and 30.0 
kg/m2. 
Obese: Obese is defined as having a BMI greater than or equal to 30.0 kg/m2. 
Delimitations and Limitations 
 Participants in this study were overweight and obese men and women of at 
least 18 years of age from the Phoenix area. They were non-smokers, had never 
been diagnosed with type 1 or 2 diabetes, had no unresolved infections, diseases, 
or inflammatory conditions, and were not pregnant or lactating. They were weight 
stable for 6 months prior to enrolling in the study, were not planning to lose 
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weight over the 3 month study duration, and had a body fat of at least 20% for 
men and 25% for women at the study baseline. The body fat parameter was 
implemented to ensure that a BMI of greater than 25.0 kg/m2 primarily reflected 
higher adiposity rather than lean body mass. The inclusion criteria were 
established to include a population most likely to be at risk of dyslipidemia and 
inflammation. Thus, results cannot be generalized to individuals who do not fit 
these criteria or to the American population as a whole. 
 Because participants will only be consuming tart cherry juice for a total of 
28 days, it is possible that this may not be enough time to elicit changes in serum 
lipids and inflammatory markers. The compliance of the participants is another 
factor that must be considered in the study. It is expected that participants will 
avoid other high anthocyanin containing fruits and fruit juices, and that diet and 
exercise will remain consistent throughout the duration of the study. This will be 
evaluated by having participants submit one 24-hr dietary record per week and a 
physical activity questionnaire at the completion of each 4-week study arm. It will 
be assumed that the dietary records will reflect typical daily intake.  
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Chapter 2 
Review Of Literature 
Chronic Disease 
The increasing prevalence of chronic disease is becoming a global 
epidemic and, according to a report published by the World Health Organization 
(WHO) in 2005, kills approximately 17 million people annually (17, 17, 17).  In 
the United States alone, chronic conditions such as CVD, cancer, and diabetes are 
responsible for 7 out of every 10 deaths, and in 2005 it was estimated that nearly 
1 out of every 2 adults suffered from one or more forms of chronic illness (18). 
CVD is an umbrella term referring to all diseases that affect the cardiovascular 
system, but frequently refers to those associated with atherosclerosis and the 
narrowing of the arteries, such as coronary heart disease (CHD). Of all chronic 
diseases, CVD has the highest mortality rate and is the leading cause of death in 
the United States, accounting for 34.3 percent of all deaths in 2006 (19). Although 
CVD (including heart disease and stroke) has consistently remained the leading 
cause of death in the United States since 1919 (20), the prevalence of diabetes is 
escalating at an alarming rate. Between 1958 and 2008, the number of people with 
diabetes has increased more than 10-fold from 1.6 million to 18.8 million, and in 
2007 nearly 8 percent of adults over 20 years of age had been diagnosed with the 
disease (21).  Based on current trends, the CDC estimates that by 2050 the 
number of people with diabetes will double or even triple (22). Diabetes and CVD 
share many of the same risk factors, a cluster of symptoms which have been 
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termed the metabolic syndrome. The National Cholesterol Education Program’s 
Adult Treatment Panel III report (NCEP ATP III) included abdominal obesity, 
atherogenic dyslipidemia (identified by low serum concentration of HDL 
cholesterol and high triglycerides), hypertension, insulin resistance/glucose 
intolerance, thrombosis, and inflammation (clinically recognized by elevated CRP 
levels) as the 6 major components of the metabolic syndrome (23). Obesity, 
defined as a BMI > 30 kg/m2, is a risk factor for both CVD and metabolic 
syndrome. Similar to trends seen in diabetes, the prevalence of obesity in the 
United States has drastically increased over the past several decades, more than 
doubling since 1980 (24). The most recent reports published by the CDC estimate 
that 33.8% of American adults age 20 and older are obese (25).  
Inflammation 
 Inflammation is a normal biological response that occurs when tissues 
become injured or infected, functioning to protect the body from foreign 
pathogens and particles, to remove dead and damaged cells, and to initiate the 
healing process (5). The affected tissues produce inflammatory cytokines and 
chemokines, which in turn function as part of a signaling pathway to orchestrate 
the inflammatory response by regulating target cells and other mediators of 
inflammation. Inflammation must occur in order for infections to be resolved and 
for wounds to heal, and can be categorized as either acute or chronic. Acute 
inflammation occurs when body tissues are first exposed to an injury, irritant, or 
infection, and progresses to chronic inflammation if the stimulant is not removed 
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(26). Chronic inflammation is associated with the simultaneous repair and 
destruction of inflamed tissues, as well as an alteration in the types of cells 
involved in the inflammatory response. Some of the primary cytokines and 
chemokines involved in inflammation include tumor necrosis factor-alpha (TNF-
α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-10 (IL-10), and 
monocyte chemotactic protein-1 (MCP-1). TNF-α and IL-1β are potent cytokines 
and key mediators of inflammation and both induce fever and IL-6 synthesis (IL-6 
is also secreted by adipocytes). IL-6 in turn acts along with TNF-α to stimulate 
the liver to produce acute phase proteins (27), which participate in the 
inflammatory response through modulation of the immune system. CRP is one 
such acute phase protein, and is particularly significant in that it is both a risk 
factor and a prognostic marker for CHD and its progression (28). MCP-1 is a 
chemokine that is responsible for activating certain types of cells, such as 
monocytes, and provoking their migration to inflamed tissues (27). Once in the 
inflamed regions monocytes can differentiate into phagocytic macrophages, 
which act immunologically to clear debris in the cell and defend against foreign 
bodies (29). Macrophages contribute to the cyclical nature of chronic 
inflammation by producing IL-1β, TNF-α, and additional MCP-1, and also play a 
significant role in the progression of atherosclerosis through plaque formation 
(27, 30). IL-10 is an anti-inflammatory cytokine that has inhibitory effects on the 
production of pro-inflammatory cytokines (27), and is therefore very important in 
ameliorating chronic inflammation. Chronic inflammation is problematic in that it 
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tends to be systemic, generating additional inflammatory sites in other regions of 
the body, and plays a primary role in the etiology of many chronic diseases (26).  
Obesity and Inflammation 
 CVD, diabetes, and obesity are interrelated in that they are each associated 
with chronic low-grade inflammation. Obesity refers to an accumulation of 
adipose tissue and is a major contributor to inflammation. Recent studies have 
exposed the biologically active nature of adipocytes and their ability to modulate 
the inflammatory response by functioning as an endocrine organ that secretes 
adipokines, chemokines, and cytokines (29). In a review article by Gustafson 
(30), mammalian adipose tissue is characterized as white adipose tissue (WAT) or 
brown adipose tissue (BAT).  These two forms are similar metabolically but differ 
in that WAT primarily stores energy, while BAT dispels energy as heat. WAT 
plays an active role in the pathophysiological processes leading to the 
development of inflammatory diseases, and is composed of both subcutaneous 
and visceral adipose tissue. Subcutaneous adipose tissue stores most of the body’s 
energy reserves and resides in the upper and lower body, while visceral adipose 
tissue surrounds and supplies the internal organs with energy.  
Adipose tissue is composed of mature adipocytes and a group of smaller 
cells that include pre-adipocytes, fibroblasts, and macrophages among many 
others (29). The adipocyte is a multifunctional cell, engaging in lipid synthesis, 
lipid storage, and the secretion of both pro-inflammatory and anti-inflammatory 
factors (30). Under normal circumstances, adipose tissue primarily secretes anti-
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inflammatory molecules, but as lipid accumulates and cells hypertrophy, the 
adipoctyes, preadipocytes, and macrophages within the adipose tissue can secrete 
a variety of inflammatory cytokines and hormones such as CRP, resistin, 
inducible nitric oxide synthase (iNOS), IL-6, and MCP-1 (31-34). Enlarged 
adipocytes also secrete the hormone leptin, which is pro-inflammatory and 
decreases the secretion of adiponectin, a hormone with anti-inflammatory 
properties (29).  
Visceral adipose tissue has a higher rate of lipolysis (fatty acid turnover), 
an increased infiltration of inflammation-inducing macrophages, and a higher 
expression of IL-6, MCP-1, and additional inflammatory related markers than 
subcutaneous adipose tissue (35, 36, 36). With increasing adiposity, monocytes 
move from the blood to adipose tissue where they differentiate into inflammatory 
macrophages and are activated to express inflammatory cytokines such as MCP-1, 
IL-6, and TNF-α (30). There is evidence to suggest that macrophages may be 
attracted to high levels of necrotic tissue induced by hypoxia in the expanding 
adipocytes(29). Visceral adipose tissue contains a higher concentration of 
infiltrated macrophages ((36), and macrophages may be a primary source of 
circulating inflammatory molecules associated with obesity (29), providing one 
possible explanation for intra-abdominal adiposity (as measured by WC) being a 
component of the metabolic syndrome and an independent risk factor for CVD 
and diabetes. 
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Figure 1. The cycle of inflammation between macrophages and adipocytes in 
obese visceral adipose tissue increases chronic disease risk. Adapted from Hirai, 
S. et al., 2010.(37). 
 
Obesity, Inflammation, and the Vasculature 
The inflammation associated with obesity also exerts a negative effect on 
the vasculature within the body, leading to an increased risk of atherosclerosis and 
CVD. Epicardial adipose tissue (EAT) is the deposition of visceral fat around the 
heart and coronary arteries that is associated with intima-media thickness and the 
inflammatory response that contributes to disease etiology (38). Similar to 
visceral adiposity, EAT is subject to macrophage infiltration and is also a source 
of bioactive molecules including resistin, TNF-α, and IL-6 (38, 39), all of which 
contribute to chronic inflammation and adverse affects on cardiac function. 
Patients with coronary artery disease have a higher level of macrophage 
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infiltration into EAT (39). Perivascular adipose tissue (PAT) refers to the 
deposition of fat around the blood vessels, which may contribute to vascular 
stiffness observed in the obese (40). Like EAT, PAT is metabolically active and 
releases a variety of inflammatory cytokines and factors that act to attenuate 
vascular relaxation and health (41).   
A large accumulation of PAT may be associated with the secretion of an 
unfavorable profile of relaxation factors, atherogenic cytokines, and smooth 
muscle growth factors that result in adverse function and morphological 
alterations of blood vessels (40). The inflammatory cytokine TNF-α plays a 
primary role in deterring the healthy relaxation of blood vessels by inhibiting 
endothelial nitric oxide (NO) vasodilation, which leads to subsequent arteriole 
constriction (42). The increased deposition of PAT is also associated with a 
reduction in the adipokine adiponectin, which modulates the inflammatory 
pathway in a variety of ways and has a major impact on endothelial function. 
Adiponectin opposes the negative effects of TNF-α on the blood vessel by 
decreasing inflammation and adhesion molecule expression, macrophage 
recruitment and TNF-α production, formation of atherosclerotic foam cells 
(produced by lipid accumulation in macrophages), and reducing platelet 
aggregation and smooth muscle cell proliferation(43-45). In addition, as a 
regulator of endothelial NO production, adiponectin helps directly determine 
blood vessel tone (46). The obesity-associated reduction of adiponectin clearly 
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has a detrimental effect on the cardiovascular system and greatly contributes to 
vascular complications. 
Cholesterol and Lipoproteins 
 Cholesterol is a type of lipid that has multiple functions in the body and is 
characterized by a four-ring core structure. It exists only in animal tissues and is 
an essential component of cell membranes, and a precursor for bile acids, steroid 
sex hormones, and vitamin D (47). Although it is required physiologically, 
cholesterol can be synthesized endogenously in the liver and is therefore not an 
essential dietary component. Dietary intake, however, can affect cholesterol 
synthesis, as saturated fatty acids have been demonstrated to enhance its 
endogenous production. However, contrary to what might be expected, dietary 
consumption of cholesterol has a very minimal impact on serum cholesterol 
concentrations (47). 
 Lipoproteins are compounds comprised of lipids and proteins that function 
to transport hydrophobic lipids through the blood to tissues (47). The structure of 
lipoproteins confers stability in the aqueous environment of the blood, consisting 
of a hydrophilic outer shell in which the polar components of proteins and 
phospholipids are situated, and an inner surface lined with the hydrophobic 
portions of proteins and phospholipids. The outer layer of lipoproteins also 
contains apolipoproteins, which confer specificity to the lipoproteins, permitting 
recognition by their corresponding cellular receptors (47). Being insoluble in 
water, triglycerides and cholesterol esters reside in the core of the lipoprotein 
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where they are shielded from contact with the blood. When dietary fats such as 
triglycerides, phospholipids, and cholesterols are ingested, they are emulsified by 
bile salts and incorporated into water-soluble micelles, which enter enterocytes 
during absorption. Upon reaching the enterocyte, the lipids are released from 
micelles and are incorporated into lipoproteins, which travel through the 
lymphatic system and into the bloodstream. The four major classes of lipoproteins 
include chylomicrons, very low-density lipoproteins (VLDL), low-density 
lipoproteins (LDL), and high-density lipoproteins (HDL), and each is categorized 
based on size and the lipid and protein composition that determines their density 
(23). The higher the ratio of protein to lipid, the greater the density of the 
lipoprotein. Chylomicrons have the lowest density of the lipoproteins, being 
composed of 88% TG, 7% phospholipids (PL), 4% cholesterol, and only 1% 
protein. Chylomicrons transport dietary lipids from the enterocyte through the 
lymph system, the blood, and then to the liver (47). When in the bloodstream, 
lipoprotein lipase (LPL) hydrolyzes and releases TG from the chylomicron to the 
adipose tissue, and the chylomicron and its remaining contents (referred to as a 
chylomicron remnant) then return to the liver.  
 VLDLs are composed of 54% TG, 22% cholesterol, 16% PL, and 8% 
protein (48) and transport TG from the liver to body tissues and adipose tissue. 
TG are also transferred from VLDL to HDL in exchange for cholesterol through 
the action of cholesterol esterase transport protein (CETP) (47). As VLDL 
progressively loses its TG and fatty acids, cholesterol becomes more concentrated 
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and the lipoprotein temporarily transitions to an intermediate density lipoprotein 
(IDL) and then ultimately to LDL. When the level of cholesterol in the IDL 
exceeds the level of TG, the IDL is officially recognized as LDL.  LDL is 
comprised of 46% cholesterol, 22% PL, 21% protein, and 11% TG (48), and an 
elevated concentration is considered the primary risk factor for CHD. 
 HDL functions in opposition to LDL, as LDL transports cholesterol away 
from the liver to tissues, and HDL carries excess cholesterol back to the liver to 
be excreted in bile or stored for later use (47). This function of HDL is referred to 
as reverse cholesterol transport, and is considered to be protective against CHD. 
HDL contains the highest quantity of protein and the lowest quantity of TG, and 
is comprised of 50% protein, 26% PL, 20% cholesterol, and 4% TG (48). 
 
Figure 2. Metabolic pathway of lipoproteins. Adapted from Olson, R. E., 1998. 
(48). CM indicates chylomicron, FFA indicates free fatty acids, LCAT indicates 
lecithin-cholesterol acyltransferase, LPL indicates lipoprotein lipase, A, B, C, and 
E indicate apolipoprotein A, B, C, and E. 
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 Triglycerides account for approximately 95% of dietary fat and their main 
function is to provide energy to body tissues. They are also the primary storage 
form of fat in adipocytes. Although the association between elevated LDL 
cholesterol and CHD risk is well established and understood, the relationship 
between elevated TG and CHD has been somewhat more ambiguous. However, 
many studies suggest that elevated concentrations of TG increase CHD risk 
independently of cholesterol levels (23, 49). Cullen conducted a meta-analysis of 
17 prospective research studies in which HDL and LDL cholesterol were 
controlled for, pooling nearly 11,000 women and more than 46,000 men, and 
found that an 88 mg/dL increase in TG concentration significantly increased CVD 
risk by 37% in women and 14% in men (p < 0.05) (49). These results support the 
premise that hypertriglyceridemia is an independent risk factor for CHD.   
Dyslipidemia 
 Dyslipidemia is a condition characterized by an independent, elevated 
concentration of LDL-cholesterol and TG and a reduced concentration of HDL-
cholesterol (singly or in combination), which increases the risk of developing 
CHD (23). The NCEP is an organization established to create evidence-based 
guidelines for the clinical prevention, treatment, and management of dyslipidemia 
(23). The NCEP has defined optimal total cholesterol levels as < 200 mg/dL, 
borderline high as 200 – 239 mg/dL, and high as > 240 mg/dL. Optimal LDL 
cholesterol is defined as < 100 mg/dL, near optimal as 100 – 129 mg/dL, 
borderline high as 130 – 159 mg/dL, high as 160 – 189 mg/dL, and very high 
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LDL cholesterol was determined to be ≥ 190 mg/dL (Table 1). Serum LDL-
cholesterol values exceeding 100 mg/dL are considered to be atherogenic, with 
higher LDL cholesterol concentrations positively correlating with an increased 
occurrence of CHD. Therefore, reductions in LDL cholesterol levels are 
considered to be protective against CHD. However, NCEP targets for LDL-
cholesterol reductions become progressively stringent as the number of CHD risk 
factors in a dyslipidemic individual increase. There is an inverse relationship 
between CHD risk and HDL cholesterol concentration, and high levels are 
considered to be protective against CHD. The NCEP has defined low HDL 
cholesterol as < 40 mg/dL and high HDL cholesterol as ≥ 60 mg/dL (Table 1).  
 Elevated TGs are also an independent risk factor for CHD and impact 
serum LDL and HDL cholesterol concentrations. NCEP has set the optimal TG 
level at < 150 mg/dL, borderline high as 150 – 199 mg/dL, and very high TG 












Total Cholesterol n/a < 200 n/a 200 - 239 > 240 n/a 
LDL cholesterol n/a < 100 100 - 129 130 - 159 160 - 189 ≥ 190 
TG n/a < 150 n/a 150 - 199 200 - 499 ≥ 500 
HDL cholesterol < 40 n/a n/a n/a ≥ 60 n/a 
Adapted from the Third Report of the National Cholesterol Education Program 
(NCEP) expert panel on detection, evaluation, and treatment of high blood 
cholesterol in adults (Adult Treatment Panel III) final report, 2002. (23). 
 
Because dyslipidemia plays a pivotal role in the development of CHD, it is 
necessary to understand the risk of developing dyslipidemia, the actions that can 
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be taken to lower such risk, and the etiology of the condition. The Framingham 
Offspring Study was conducted between 1971 and 2001 to determine the risk of 
developing dyslipidemia over a thirty year period, and included 4701 men and 
women between the ages of 30 and 59 years at baseline. The study sample 
included participants with and without various forms of dyslipidemia, but 
participants who experienced myocardial infarction or TG exceeding 400 mg/dL 
were excluded in the statistical analysis. An examination and fasting blood draw 
was performed approximately every 4 years during the study period, and both the 
prevalence and the risk of developing dyslipidemia was determined in the sample 
population. The prevalence of borderline-high LDL cholesterol (defined as ≥ 130 
mg/dL and/or lipid modifying drug use) was determined to be 24% in women and 
44% in men in the 30-34 age group, 36% in women and 57% in men in the 40-44 
age group, and 51% in women and 61% in men in the 50-54 age group. The 
prevalence of high LDL cholesterol (defined as ≥ 160 mg/dL and/or lipid 
modifying drug use) was demonstrated to be 6% in women and 16% in men in the 
30-34 age group, 12% in women and 24% in men in the 40-44 age group, and 
24% in women and 29% in men in the 50-54 age group (50). The prevalence of 
low HDL cholesterol (defined as < 40 mg/dL) was less dependent upon age and 
was determined to be approximately 40% in men and 10% in women. Cobain et 
al. determined that the risk of developing borderline high LDL cholesterol after 
30 years was approximately 69% for women and 81% for men in the 30-34 age 
group at baseline, 81% for women and 82% for men in the 40-44 age group, and 
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83% for women and 82% for men in the 50-54 age group. The 30-year risk of 
developing high LDL cholesterol was demonstrated to be approximately 43% for 
women and 52% for men aged 30-34, 55% for women and 57% for men aged 40-
44, and 57% for women and 59% for men aged 50-54 at baseline. The risk of 
developing low HDL cholesterol after 30 years was determined to be 
approximately 27% for women and 67% for men in the 30-34 age group, 29% for 
women and 65% for men in the 40-44 age group, and 28% for women and 67% 
for men in the 50-54 age group at baseline. After 30 years, approximately 20-40% 
of the sample population developed a combination of high LDL and low HDL 
cholesterol, putting the participants at significant risk for developing CHD (50). 
Although the generalizability of study results to the entire American population is 
limited due to a lack of geographic and ethnic diversity within the sample 
population, this study clearly demonstrates that dyslipidemia poses a significant 
risk to public health and must be dealt with. 
Dyslipidemia and Inflammation in the Etiology of Atherosclerosis 
Hypercholesterolemia may result in the accumulation, oxidation, and 
modification of lipids in the vascular endothelium, leading to endothelial 
dysfunction, chronic inflammation, and CVD (51). It has become increasingly 
evident that chronic inflammation is involved in the atherosclerotic process. 
Atherosclerosis refers to the accumulation of lipids, calcium, and connective 
tissue within the arterial endothelium that initiates plaque formation and the 
thickening of arteries, subsequently producing the stenosis and/or thrombosis (51) 
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associated with CHD. The pathogenesis of atherosclerosis is initiated by elevated 
levels of LDL-cholesterol that accumulate in the arterial intima and are subject to 
oxidation by reactive oxygen species (ROS) (52). Endothelial dysfunction also 
occurs in these early stages of atherosclerosis, as a variety of mechanisms 
(including reactivity with ROS) contribute to the reduced production and 
bioactivity of the vasodilator NO (28). In addition to regulating vascular tone, 
endothelial NO also acts to reduce leukocyte adhesion to endothelial cells, the 
ability of smooth muscle to proliferate in forming plaques, and the aggregation of 
platelets, all of which are important mechanisms in the process of atherogenesis 
and will be described in more detail below.  
The reduced capacity of NO to regulate the vascular endothelium is 
accompanied by an elevated expression of adhesion molecules, which permit the 
increased binding of monocytes and T lymphocytes to the endothelium and entry 
into the arterial intima (28). Once in the intima, the monocytes differentiate into 
macrophages and internalize oxidized LDL to become foam cells, subsequently 
secreting pro-inflammatory cytokines such as TNF-α and IL-1β (28). T 
lymphocytes also become activated in response to oxidized LDL, secreting pro-
inflammatory cytokines and interacting with macrophages to elicit the production 
of the tissue factor matrix metalloproteinase (MMP), which in turn functions to 
increase the inflammatory response (28). This continuous cycle of oxidation, 
endothelial injury, and inflammation stimulates vascular smooth muscle cells to 
proliferate and produce collagen and elastin, ultimately protruding into the intima. 
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Additional factors promote the death of smooth muscle cells and macrophages, 
which accumulate as necrotic debris and contribute to inflammation (51). The 
collagen and elastin produced by smooth muscle cells create a fibrous cap over 
the growing arterial lesion that is susceptible to rupture, potentially producing a 
thrombus that could result in blood vessel occlusion. The growing plaque and its 
fibrous cap may also cause blood vessel stenosis, potentially accompanied by 
ischemia. Elevated levels of LDL-cholesterol and the modification that occurs as 
a result of oxidation play a primary role in the pathology of atherogenesis (52). 
By promoting mature macrophage transformation, provoking MCP-1 production 
by endothelial cells, enhancing foam cell formation and oxidized LDL-cholesterol 
uptake, and stimulating monocyte expression of pro-inflammatory cytokines, 
oxidized LDL-cholesterol initiates and promotes the inflammatory process 
associated with the development of CVD (52).   
 
Figure 3. Oxidized LDL acts to promote inflammation and atherosclerosis. 
Adapted from Kris-Etherton, P.M. et al., 2004. (53). 
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Functional Foods 
Chronic disease development and the inflammatory and oxidative 
processes underlying their pathogenesis can be modified by several behavioral 
factors, one of which is diet. Functional foods are those that contain bioactive 
components that are believed to provide physiological benefits beyond what basic 
nutrients are expected to supply, promoting health and/or preventing the 
development and progression of many diseases (54). Epidemiological studies 
have clearly demonstrated an association between increased fruit and vegetable 
intake and a reduced risk of CVD, heart disease, and type 2 diabetes (2-4), and it 
is plausible that the beneficial effects of fruit and vegetable consumption may be 
attributed to the specific phytochemicals that these foods contain. Polyphenols are 
a diverse class of plant-derived compounds found in fruits and vegetables that are 
bioactive agents, conferring a wide variety of potential physiological benefits (5). 
Polyphenols are comprised of 2 or more hydroxyl groups attached to a benzene 
ring and can be divided into 5 major subclasses: cinnamonic acids, chalcones, 
flavanoids, procyanidins, and anthocyanins (5). Anthocyanins are a group of 
water-soluble pigments that give orange, blue, red, and purple fruits, vegetables, 
and flowers their characteristic colors, and are present in high levels in black 
currants, purple grapes, strawberries, raspberries, blue berries, and cherries (6, 
55).  The literature has identified over 500 different anthocyanins, which are 
composed of the aglycone anthocyanidin linked to a sugar to create a more stable 
glycoside that is water-soluble (56). The basic structure of the aglycone 
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anthocyanidin, as shown in Figure 4,  consists of a flavilium or 2-phenyl-
benzopyrilium cation, and anthocyanins are differentiated primarily based on the 
number and position of the methoxyl and hydroxyl groups attached to the base 
(56). The most frequently encountered anthocyanins in fruits and vegetables 
include delphinidin, pelargonidin, malvidin, petunidin, peonidin, and cyanidin 
(Figure 4) (56). Studies have demonstrated that anthocyanins may function as 
antioxidants and diminish the formation of free radicals, favorably impact 
dyslipidemia, and reduce inflammation (6, 57, 58). 
 
Figure 4. Structures of 6 anthocyanins common in fruits and vegetables. Adapted 
from de Pascual-Teresa, S. et al., 2010 (56). 
 
Anthocyanins  
 Many studies suggest that anthocyanins may offer protection against the 
formation of free radicals and oxidative stress (6, 9, 57, 59), and this is 
particularly important because the generation of free radicals is thought to 
contribute to the pathology of chronic disease (60). Antioxidant enzymes and 
compounds neutralize the oxidation of cells and their constituents by free radicals. 
ROS are continuously created as a byproduct of metabolism and can damage body 
systems if antioxidants are unable to neutralize them (9). When such an imbalance 
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between ROS production and antioxidant availability occurs, the free radicals can 
attack lipids (as happens in LDL-cholesterol oxidation), proteins, and even DNA, 
resulting in the destruction of cell membranes and the impairment of cellular 
functions (9). Limiting the exposure of LDL-cholesterol to free radicals by 
improving antioxidant defenses may reduce its subsequent oxidation, thereby 
decreasing the role of LDL-cholesterol in promoting atherogenesis. A portion of 
the high antioxidant capacity of anthocyanins is thought to be attributed to their 
unique structure, which consists of multiple hydroxyl groups that can donate 
electrons to neutralize a radical (61).  The antioxidant activity of anthocyanins has 
been reported to increase as the number of hydroxyl groups increases, and to 
decrease with the glycosylation of anthocyanidins (59). Direct antioxidant activity 
by anthocyanins has also been attributed to their capacity to chelate metals such 
as Fe (II), which catalyzes lipid oxidation (62). The resulting Fe (II) complexes of 
anthocyanins are inert and unable to engage in lipid peroxidation but purportedly 
retain their radical scavenging abilities (63).  
The ability of anthocyanins to neutralize free radicals and chelate metal 
ions has been demonstrated at high concentrations in vitro (8, 9, 16, 63). The 
actual plasma concentrations of anthocyanins and their metabolites that occur in 
vivo are much lower due to relatively low absorption, and this may alter their 
capacity to act by these mechanisms. While both the parent compound and many 
of its degradation products have been shown to retain their direct radical 
scavenging activity following absorption (9), a study conducted by Kay et al. (64) 
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determined their absorption rate to be only 0.15% of the initial dose. The low 
bioavailability and rapid elimination of anthocyanins and their metabolites in vivo 
have led some researchers to suggest that the increased anti-oxidant activity 
observed in many studies may be better explained by an ability to inhibit 
oxidation through indirect rather than direct mechanisms. It has been proposed 
that anthocyanins may upregulate the expression of certain antioxidant and 
detoxifying enzymes, which in turn function to directly neutralize free radicals 
and protect against the harmful effects of oxidative stress (65). SOD and Gpx are 
two such antioxidant enzymes that have demonstrated an increase in activity in 
response to anthocyanin consumption (10, 66, 67). 
Although research has shown anthocyanins to protect against oxidative 
stress and attenuate the inflammatory response, these phytochemicals have also 
been demonstrated to modulate inflammation in other ways. Cyclooxygenase 
(COX) is an enzyme that catalyzes the conversion of arachidonic acid to pro-
inflammatory prostaglandins and thromboxanes. The two major isoforms of COX 
include COX-1 and COX-2, with COX-1 being expressed in a variety of tissues 
and COX-2 being induced at sites of inflammation, including within macrophages 
and mast cells following stimulation by pro-inflammatory cytokines (7). NSAIDs 
such as aspirin, ibuprofen, and Advil reduce inflammation by inhibition of the 
COX-1 and 2 pathways, and several studies have reported that anthocyanins also 
have the capacity to inhibit COX-enzyme activity (8-10). In addition to the COX-
1 and 2 enzymes, TNF-α, IL-6, CRP, MCP-1, and NO (generated by iNOS) are 
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biomarkers that also stimulate the inflammatory response. Studies have 
demonstrated that these pro-inflammatory cytokines, chemokines, and messenger 
molecules are significantly reduced following anthocyanin consumption (13, 14, 
66, 68), thereby providing additional mechanisms for the anti-inflammatory 
effects associated with anthocyanins. 
There is research to suggest that anthocyanins may also have a beneficial 
effect on dyslipidemia. Studies using both human and rodent models have 
reported an increase in HDL (67, 69), and reductions in total cholesterol (12, 67, 
70),  LDL cholesterol (67, 69, 70), and triglycerides (12, 67, 70) following the 
consumption of anthocyanin-rich tart cherries. There are several proposed 
mechanisms for the positive effect of anthocyanins on serum lipid parameters. 
One such explanation involves the inhibition of CETP in reverse cholesterol 
transport. It has been shown that anthocyanins act to significantly lower the 
activity of CETP, resulting in an increase in HDL-cholesterol and a decrease in 
LDL-cholesterol (69). In addition, anthocyanin supplementation has been 
demonstrated to induce cholesterol efflux from macrophages and foam cells in 
mice, which may act as a potential mechanism in humans to further aid in reverse 
cholesterol transport (71). Anthocyanins may also function to improve serum lipid 
homeostasis by stimulating the upregulation of the LDL receptor (LDLR) (57). 
LDLR regulate cholesterol homeostasis by eliminating LDL-cholesterol from 
circulation. A higher level of functional LDLR will generally correlate with a 
greater clearance of LDL-cholesterol from the blood. It has been demonstrated 
   28 
that anthocyanin supplementation induces the expression of LDLR genes in a 
dose dependent manner, leading to an increase in the number of LDLR on cell 
surface membranes (57).  
Anthocyanins in Tart Cherries 
 Anthocyanins are particularly high in cherries and highly concentrated in 
the skin of the fruit, accumulating during the ripening process (55, 72). Cherries 
consist of more than 100 different species, of which the “sweet” and “sour” (tart) 
cherry species are perhaps the most recognized (72). Sweet and tart cherries are a 
good source of many vitamins, minerals, and phytochemicals, but tart cherries 
contain considerably more total phenolics, which has been partially attributed to 
the higher content of anthocyanins in tart cherries (72). One of the most 
frequently encountered anthocyanin in cherries is cyanidin-3-glucoside (see 
Figure 4), and the quantity of anthocyanins in cherries produced by various 
cultivars has been measured at 30-79 mg of cyanidin-3-glucoside equivalents 
(CGE)/100g in sweet cherries and 45-109 mg CGE/100g in tart cherries (72). The 
scientific designation for tart cherries is Prunus cerasus L., and although they are 
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TABLE 2 
Tart cherry nutrient composition 
Nutrient 78 g of tart cherries 
Calories 36 
Total fat, g 0.34 
Protein, g 0.71 
Carbohydrate, g 8.54 
           - Dietary fiber, g 1.2 
           - Sugar, g 6.99 
Iron, mg 0.21 
Calcium, mg 10 
Sodium, mg 1 
Magnesium, mg 7 
Pottasium, mg 96 
Vitamin A, IU 674 
Vitamin C, mg 0.7 
Vitamin E, mg 0.04 
Adapted from USDA Commodity Food Fact Sheet for Schools & Child Nutrition 
Institutions (73). 
 
 Because anthocyanins are relatively unstable pigments, their concentration 
in tart cherries can be altered by many physical and environmental factors (72, 
74). Increasing temperature and pH during storage and processing greatly 
influence the rate and degree of anthocyanin degradation (74). Various 
anthocyanin degradation products exhibit varying degrees of activity within the 
body (74). Upon consumption, the anthocyanins from tart cherries are absorbed in 
the intestine (aglycones such as cyanidin can be absorbed directly whereas 
glycosylated forms must be hydrolyzed prior to absorption), and then conjugated 
in the intestine and liver by methylation, sulfation, and glucuronidation. The 
conjugated anthocyanin derivatives are then attached to albumin and transported 
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through the blood to peripheral tissues where they are needed before being 
eliminated in the bile and/or urine (72). 
Kay et al. conducted a study using a sample population of 3 healthy men 
to determine the profile and pharmacokinetic properties of metabolites produced 
following the consumption of cyanidin-3-glycoside (a major anthocyanidin in tart 
cherries) and found that glucuronidation was the primary metabolic pathway for 
anthocyanin metabolism, followed by methylation. Glucuronidated and 
methylated metabolites were detected at levels twice that of the intact (parent) 
compound, and the absorption of these compounds over a 24-hr period was found 
to be extremely low at 1072 mcg, or 0.15% of the initial dose. The appearance of 
the parent compound and metabolites in the serum reached a peak at 2.8 hrs and 
the maximum excretion in the urine was observed at 3.7 hrs, indicating a very 
rapid absorption and elimination. Although anthocyanin absorption was low, the 
sample size in the study was very small (n = 3) and many anthocyanin metabolites 
have yet to be identified (64), prohibiting definitive conclusions.   
Additional research on anthocyanin metabolites as they exist in circulation 
is necessary to determine their capacity to perform biological activities. Amidst 
the mounting evidence demonstrating the many health benefits potentially 
conferred by anthocyanins, the high anthocyanin content of tart cherries makes 
them a very attractive functional food for lowering disease risk. Many studies 
have been conducted using in vitro, animal, and human models to determine the 
   31 
effects of tart cherry supplementation on oxidation, inflammation, and 
dyslipidemia. 
Tart Cherry Supplementation, Oxidation, and Inflammation In Vitro 
 Increased levels of oxidative stress are intimately related to inflammation 
and the pathology of chronic disease. Much research has been conducted in vitro 
to determine the potential of compounds derived from tart cherries to function as 
antioxidant and anti-inflammatory agents. Wang et al. (9)conducted an in vitro 
study to compare the anti-inflammatory and antioxidant activities of the 3 major 
anthocyanins from tart cherries (cyanidin 3-glucosylrutinoside, cyanidin 3-
rutinoside, and cyanidin 3-glucoside) and their aglycon (cyanidin) to the activity 
of commercial products. The anthocyanin compounds were assayed for 
antioxidant activity based on the reduction of fluorescence observed when free 
radicals produced by a pro-oxidant (Fe2+) degrade a phospholipid bound to a 
fluorescent probe. Cox-1 and -2 anti-inflammatory activities of the various 
commercial NSAIDs and the anthocyanin compounds were determined through 
the use of prostaglandin endoperoxide H synthase-1 and -2 isozymes (PGHS-1 
and -2) and their capacity to convert acachidonic acid to prostaglandins. At 2 mM 
concentrations, the activities of all three anthocyanins and cyanidin were 
comparable to the commercial antioxidants BHA and BHT, and were far superior 
to α–tocopherol (vitamin E). Although the 3 major anthocyanins showed little 
anti-inflammatory activity, cyanidin was observed to have COX-1 and -2 anti-
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inflammatory activity superior to aspirin, but less than the NSAIDs ibuprofen and 
naproxen (9). 
Seeram et al. (74) conducted a similar study by characterizing and 
determining the anti-inflammatory and antioxidant activities of the degradation 
products. The 3 major anthocyanins and cyanidin were added to McCoy’s 5A 
medium supplemented with 10% fetal bovine serum to isolate and characterize 
the degradation products. Protocatechuic acid, 2,4-dihydroxybenzoic acid, and 
2,4,6-trihydroxybenzoic acid were determined to be the primary degradation 
products. Fluorescent spectroscopy was again used to compare the antioxidant 
capacity of the anthocyanin compounds to commercial products, and COX-1 and -
2 assays were conducted by adding 10 µL of arachidonic acid to an enzyme 
preparation using ram seminal vesicles and a preparation from insect cell lysate to 
determine anti-inflammatory activities. At a concentration of 100 µM, the 
degradation products were not observed to have Cox-1 and -2 inhibition activities 
compared to Naproxen, Celebrex, Ibuprofen, or Vioxx. However, the antioxidant 
activity of 50 uM of protocatechuic acid was comparable to BHT, BHA, and the 
commercial antioxidant tert-butylhydroquinone (TBHQ). 
Mulabagal et al. (16) analyzed the antioxidant and anti-inflammatory 
capacity of whole extracts of cherries, examining the ability of several varieties of 
sweet and tart cherries to inhibit lipid peroxidation (LPO) and the COX-1 and -2 
enzymes. LPO inhibitory activities were determined by fluorescence spectroscopy 
as previously described, where oxidation was initiated by the addition of the pro-
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oxidant Fe2+ to the LPO assay.  To evaluate the biological activity of both water 
and lipid-soluble cherry compounds, methanol and ethyl acetate cherry extracts 
were assayed at a concentration of 250 µg/mL. The percent peroxidation 
inhibition was evaluated using water and DMSO as controls, and BHA, BHT, and 
TBHQ as positive controls. The percentage of COX-1 and -2 enzyme inhibition 
was also determined using water and DMSO as controls, and 60µM aspirin, 32 
nM Vioxx, and 26 nM Celebrex were tested as positive controls. Tart cherry 
extracts of the Balaton and Montmorency varieties demonstrated antioxidant 
capacity, inhibiting LPO by 38 to 59% respectively. Extracts of the Balaton and 
Montmorency tart cherries also showed anti-inflammatory activity, with water 
extracts having a greater capacity than the methanol or ethyl acetate extracts to 
inhibit the COX-1 and -2 enzymes. The percent inhibition of COX-1 and -2 
enzymes by water extracts of Balaton and Montmorency cherries was measured at 
91 and 87%, and 84 and 76%, respectively. 
Tart Cherry Supplementation, Oxidation, and Inflammation in Rats 
 Although results obtained from many in vitro studies suggest that 
compounds derived from tart cherries possess antioxidant activity and may have 
the capacity to function as anti-inflammatory agents, in vivo research is necessary 
to evaluate the biological activities of tart cherry derivatives following absorption 
and metabolism. Studies using rodent models have been conducted with this aim. 
Saric et al. (10) investigated the antioxidant activity and anti-inflammatory 
potential of tart cherry juice in male mice. The mice were allocated into a control 
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group, which received a diet of commercial food pellets, and two experimental 
groups, which each received commercial food pellets supplemented with 10% or 
50% Brix concentrated tart cherry juice. Each group consisted of 10 mice, which 
were fed their respective diets for a two-week period prior to testing. To 
determine the antioxidant efficacy of tart cherry juice, total SOD, Gpx, and 
catalase (CAT) activity were examined in the brain, liver, and blood (erythrocyte 
lysates), and LPO activity was measured in the liver and brain. To evaluate the 
effect of tart cherry juice on COX-2 activity, 12 days before testing all mice were 
injected with incomplete Freund’s adjuvant to elicit the inflammatory 
autoimmune disease adjuvant-induced arthritis (AIA), and then COX-2 inhibitory 
capacity was assessed in the peritoneal macrophages of the mice. The results of 
the study showed that tart cherry juice increased antioxidant activity in the liver 
and blood, although the brain was unaffected. Both the 10% and 50% 
concentrations of tart cherry juice significantly increased SOD activity in the 
blood, and the 50% concentration significantly increased SOD activity in the liver 
versus control. Gpx activity was also significantly increased in the liver at both 
the 10% and 50% cherry juice concentrations. No significant increase in CAT 
activity was observed in any of the assessed tissues. LPO was found to 
significantly decrease in the liver at the 10% concentration, although no effect 
was demonstrated in the brain at either the 10% or 50% concentration. Tart cherry 
juice was observed to oppose inflammation through inhibition of the COX-2 
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enzyme, as the 10% concentration decreased COX-2 activity by 33% and the 50% 
concentration decreased COX-2 activity by 41% versus the control. 
 He et al. (66) conducted a similar study in male Sprague Dawley rats to 
analyze the antioxidant and anti-inflammatory effects of anthocyanins extracted 
from tart cherries. As in the Saric et al. (10) study, SOD activity was assessed to 
partially determine antioxidant potential and injections of complete Freund’s 
adjuvant were used to induce AIA. The rats (12 per group) were randomly divided 
into a normal group, an AIA group, and an AIA group each receiving a low (10 
mg/kg), medium (20 mg/kg), and high (40 mg/kg) oral dosage of tart cherry 
anthocyanins. Anti-oxidative impact was determined by measuring total anti-
oxidative capacity (T-AOC), SOD, and malondialdehyde (MDA) in the blood, 
and anti-inflammatory effects were evaluated by measuring serum TNFα and 
prostaglandin E2 (PGE2) in the right hind paw (site of Freund’s adjuvant 
injection). The anthocyanins from the tart cherry juice had antioxidative effects, 
as T-AOC and SOD significantly increased in all dosage groups and MDA was 
significantly reduced. Anti-inflammatory effects were also observed as TNF-α 
and PGE2 levels declined with increasing doses of anthocyanins, reaching 
significance at 40 mg/kg. 
 In a 2009 study conducted by Seymour et al. (13), inflammation was 
assessed in male Zucker fatty rats following tart cherry supplementation. Rats 
were allocated into experimental and control groups, each containing 12 rats. The 
experimental group was fed a higher fat diet supplemented with freeze-dried tart 
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cherry powder, and the control group received a diet equivalent in calories and 
macronutrient content, but without the cherry powder. Following a 90 day period, 
tart cherry supplementation was associated with a significant reduction in the 
inflammatory cytokines TNF-α and IL-6 in both the plasma and the 
retroperitoneal fat. In the plasma, TNF-α and IL-6 were measured at 26 ± 4 and 
191 ± 22 pg/mL, respectively, in the treatment group and 43 ± 5 and 289 ± 31 
pg/mL, respectively, in the control group, corresponding to decreases of 40% and 
44%. TNF-α and IL-6 expression in the retroperitoneal fat was reduced by 3.2 and 
3.6-fold in the treatment group. A reduction in TNF-α and IL-6 gene transcription 
was also observed in rats consuming tart cherry powder, with mRNA levels 
declining by 2.9-fold and 4.5-fold. 
Cherry Supplementation, Oxidation, and Inflammation in Humans 
 Although limited in number, in vivo studies using cherries have also 
suggested effectiveness in increasing antioxidant status and reducing 
inflammation in humans. Traustadottir et al. (11) investigated the effect of tart 
cherry juice supplementation on oxidative stress in a placebo-controlled crossover 
study using a population of 12 healthy older adults, where oxidative damage was 
measured as changes in the amount of plasma F2-isoprostane following forearm 
ischemia-reperfusion (I/R). The participants were normal and overweight men and 
women (BMI of 19-29 kg/m2) aged 61-75. At baseline all subjects underwent I/R 
and were randomly assigned to either placebo or tart cherry juice. In the first arm 
of the study, the treatment group consumed 8 ounces of tart cherry juice twice 
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daily for 14 days and underwent a second I/R, followed by a 4-week washout 
period. In the second arm of the study, the I/R trial was repeated a third time, and 
then subjects consumed 8 ounces of a placebo beverage twice daily for 14 days 
and completed a fourth I/R. Subjects initially assigned to the control group 
followed the same protocol but consumed the cherry and placebo beverages in the 
reverse order. Urine was collected during the last 5 days of each study arm to 
measure markers of oxidative damage, including isoprostanes, DNA, and RNA.  
Blood was drawn subsequent to each I/R trial and was also drawn 15, 30, 60, 120, 
180, and 240 minutes after each trial. Tart cherry juice supplementation decreased 
oxidative damage following I/R, as F2-isoprostane levels in the blood were 
significantly reduced compared to placebo. In addition, urinary markers of 
oxidatively damaged DNA (measured as 8-OHdG) and RNA (measured as 8-oxo-
G) were also significantly reduced. However, markers of oxidized proteins and 
lipids were unaffected by the intervention.  
 Kelley et al. (14) conducted a study to examine the effects of cherry 
consumption on markers of inflammation in humans, but used Bing sweet cherries 
instead of tart cherries. The study participants included 18 healthy men and 
women aged 45-61 with a BMI between 20.0 and 30.0 kg/m2. The study was 
divided into three distinct segments comprised of an 8-day baseline period free of 
dietary intervention, a 28-day intervention period where 300 g of cherries were 
consumed by each subject daily, and a 28-day post-intervention period free of 
dietary intervention. Fasting blood draws occurred on day 0 and 7 of baseline, day 
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21 and 35 of the intervention period (14 and 28 days after cherry consumption 
began), and day 64 of the post-intervention period (28 days following the 
termination of cherry consumption). Plasma NO, CRP, IL-6, TNF-α, and 
regulated upon activation, normal T-cell expressed, and secreted (RANTES) were 
each among the 45 different inflammatory markers analyzed. Although the 
majority of the inflammatory markers evaluated were not affected by the 
intervention, circulating concentrations of NO, CRP, and RANTES significantly 
decreased by 18%, 25%, and 21%, respectively, by day 28 of the study. Following 
the discontinuation of cherry consumption, concentrations of CRP and NO 
partially returned to their baseline levels, suggesting the reductions were caused 
by cherry supplementation.   
In a small pilot study, Martin et al. (75) evaluated the effect of a cherry 
intervention on many of the same biomarkers of inflammation as those analyzed 
by Kelley et al (14). Participants included 10 overweight and obese healthy men 
and women aged 24 to 60, each having a BMI between 27.3 and 41.6 kg/m2. The 
study was a 10-wk randomized, crossover, placebo-controlled intervention where 
the subjects were initially assigned to either a treatment group or a control 
(placebo) group. Participants consumed either 8 ounces of 100% tart cherry juice 
or a placebo beverage equivalent in macronutrient and caloric content daily for a 
4-week period, underwent a 2-week washout period, and then switched to the 
alternate beverage. Fasting blood draws were performed at baseline (week 0) and 
at the end of each study arm (following weeks 4, 6, and 10) to measure ESR, 
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hsCRP, IL-6, IL-10, TNF-α, and MCP-1. Erythrocyte sedimentation rate (ESR), a 
measurement of chronic inflammation, was significantly reduced following cherry 
juice consumption compared to placebo. At study conclusion, TNF-α and MCP-1 
were determined to be significantly lower in those subjects starting the study 
drinking tart cherry juice than those initially assigned to consume placebo.   
 
Figure 5. Many in vitro and in vivo studies have demonstrated the potential of 
tart cherries to exert anti-inflammatory and antioxidant effects protecting against 
the development of chronic disease. Adapted from Ferretti, G. et al., 2010 (72). 
 
Tart Cherry Supplementation and Dyslipidemia in Rats 
 In addition to the studies determining the antioxidant and anti-
inflammatory capacity of tart cherries, research has also been conducted to 
evaluate effects on dyslipidemia. Studies using rat models have suggested that tart 
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cherries may have a favorable impact on blood lipid profiles. In the previously 
described 2009 study by Seymour et al. (13), Zucker fatty rats were not only 
monitored for fluctuations in inflammatory markers following tart cherry powder 
supplementation, but also for alterations in serum lipid levels. Subsequent to the 
90-day intervention period, whole blood was obtained for analysis and the total 
cholesterol and triglycerides of rats consuming the tart cherry diet were found to 
be significantly lower than that of the control group (185 ± 15 and 241 ± 18 
mg/dL compared to 207 ± 14 and 284 ± 23 mg/dL, respectively).  
 In an earlier study, Seymour et al. (12) investigated the effect of a tart 
cherry-enriched diet on serum lipid values in male Dahl-Salt Sensitive (Dahl-SS) 
rats and derived results similar to the 2009 study. Unlike Zucker fatty rats, Dahl-
SS rats are prone to developing hyperlipidemia without being obese. The rats 
were randomly divided into two groups of 12, with the treatment group receiving 
a diet supplemented with 1% freeze-dried whole tart cherry powder by weight, 
and the control group receiving a calorie and carbohydrate equivalent diet free of 
cherry powder. Following a 90-day intervention period, whole blood was 
collected for lipid analysis and total serum cholesterol and triglyceride 
concentrations were significantly lower in rats receiving the tart cherry powder 
compared to rats in the control group (75 ± 4 and 28 ± 3 mg/dL versus 87 ± 5 and 
34 ± 3 mg/dL, respectively).  
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Cherry Supplementation and Dyslipidemia in Humans 
Research evaluating the effect of tart cherries on serum lipid levels in 
humans is extremely limited and the characteristics of the selected subject 
samples are highly variable between studies, making it difficult to directly 
compare study outcomes. Many of the studies that have been conducted have also 
demonstrated contradictory results, contributing to the ambiguity associated with 
the effect of tart cherries on dyslipidemia in humans. Ataie-Jafari et al. (70) 
conducted a pilot study in a diabetes clinic in Iran to determine the effect of tart 
cherry juice on the blood lipid profiles of 19 women diagnosed with type-2 
diabetes. The women were otherwise healthy, reporting no additional chronic 
diseases, and did not use insulin. For a period of six weeks, subjects consumed 40 
g or 3 Tbsp of concentrated tart cherry juice daily. Fasting blood draws were 
performed to determine concentrations of total cholesterol, LDL cholesterol, HDL 
cholesterol, and triglycerides at baseline (week 0) and at the completion of the 
study (week 6). Although no significant changes were observed in HDL or 
triglyceride levels following tart cherry juice supplementation, a significant 
reduction did occur in total cholesterol and LDL cholesterol, with levels 
decreasing from 213.9 to 193.2 mg/dL and 118.4 to 103.6 mg/dL, respectively. 
 The effect of tart cherry juice on serum lipid concentrations was also 
examined in the previously described pilot study by Martin et al (76). In this 
study, inflammatory markers and blood lipid levels were measured in 10 
overweight and obese participants consuming tart cherry juice and placebo for 4 
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weeks each, separated by a 2-week washout period.  Fasting blood samples were 
acquired at baseline and following each arm of the study period (a total of 4 blood 
draws were performed) to determine serum levels of total cholesterol, LDL-
cholesterol, HDL-cholesterol, and triglycerides. In contrast to the results reported 
by Ataie-Jafari et al., no significant reduction was observed in total cholesterol 
and LDL cholesterol concentrations in participants consuming tart cherry juice, 
but a significant reduction in triglyceride levels was noted, which declined 14% 
from 147 ± 55 to 127 ± 45 mg/dL. No change in HDL cholesterol concentration 
was observed. 
 In the previously cited study by Kelley et al. (14), the consumption of 300 
g of Bing sweet cherries daily over a period of 28 days was associated with a 
reduction of certain biomarkers of inflammation in 18 healthy normal weight, 
overweight, and obese men and women. However, this study also examined the 
effects of Bing sweet cherries on serum lipid concentrations and reported 
outcomes different than those observed by Ataie-Jafari et al. (70) and Martin et al 
(76). Kelley et al. (14) did not report the actual serum lipid concentrations in their 
published study, but stated that lipid levels did not significantly decrease in 
response to cherry supplementation. Although each of the three studies reported 
incongruent conclusions regarding the effect of cherries on serum lipid 
concentrations in humans, the varying characteristics of the subject samples and 
sample sizes used makes direct comparison difficult. Ataie-Jafari et al. (70) used a 
sample of 19 diabetic women, Kelley et al. (14) recruited 18 healthy normal 
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weight and overweight participants, and Martin et al. (76) included 10 healthy 
overweight and obese individuals. Because Kelley et al. (14) used a study sample 
of healthy, non-obese subjects and did not report the baseline lipid values, it is 
possible that no changes were observed in serum lipids because participants’ 
values were normal to begin with and were therefore less susceptible to 
improvement through intervention.   
Cherry Study Outcomes and the Need for Further Research 
 Several pharmaceutical drugs are fairly effective in combating 
inflammation and reducing blood lipid levels, but these are frequently associated 
with many devastating and undesirable side effects, creating a demand for safe 
and natural anti-inflammatory and lipid-lowering agents. In recent years, tart 
cherries have been cited as a functional food that may have the capacity to reduce 
the oxidative damage, inflammation, and dyslipidemia associated with the 
pathogenesis of chronic disease. Several studies have documented the antioxidant 
properties of tart cherries both in vitro and in vivo, but there are much fewer 
studies exploring the effects of tart cherries on inflammation and dyslipidemia. 
Much of the research that has been conducted in these areas has used rodents, 
which possess different metabolic characteristics than humans. Therefore, results 
obtained from such studies may not be particularly applicable to humans. Of the 
few studies that have analyzed the effects of tart cherry juice on inflammation and 
serum lipid values in humans, the results have been contradictory and the 
characteristics and size of the subject sample has varied. There is a need for 
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further research in this area, especially among non-diabetic, overweight and obese 
individuals that may have a higher probability of suffering from inflammation and 
dyslipidemia. Therefore, it would be advantageous for further research to explore 























 This research study enlisted 36 overweight and obese men and women 
from the greater Phoenix area who were at least 18 years of age. Volunteers were 
recruited through email announcements, flyers mailed to departments at the ASU 
Tempe campus, and flyers placed throughout Arizona State University (ASU) 
campuses and in local businesses. The participants were classified as overweight 
or obese based on a BMI ≥ 25.0 kg/m2. For participation in the study, a minimal 
body fat of 20% for men and 25% for women were required. In addition, 
individuals were non-smokers, were not lactating or pregnant at any time during 
the study, were not taking lipid-lowering or thyroid medications, were not taking 
non-steroidal anti-inflammatory drugs (NSAIDS) regularly (as defined as 3 or 
more 600 mg doses per week or more than one 80 mg baby aspirin daily), and 
were generally healthy and free of chronic diseases such as type 1 or 2 diabetes, 
inflammatory bowel disease, arthritis, and liver disease. In addition, to be eligible 
for study participation it was required that the volunteers be weight-stable for 6 
months prior to the start of the study and throughout the study duration.  
Potential participants were initially asked a series of questions via 
telephone to see if they met basic inclusion requirements (Appendix A). 
Candidates who qualified for the study were scheduled for their first appointment 
and, upon arrival, were read a disclosure statement (Appendix B). Participants 
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provided informed consent to the protocols of the research that were approved by 
the Institutional Review Board (IRB) at ASU (Appendix C). Upon signing the 
consent form, each participant was asked to complete a brief medical history 
questionnaire, which consisted of questions regarding the use of medications and 
dietary supplements, as well as questions regarding the diagnosis of certain 
medical conditions (Appendix D). This questionnaire was used to confirm that 
potential candidates met the inclusion criteria. 
Study Design 
This study was a 4-week randomized, crossover, single-blinded, placebo-
controlled intervention. A diagram of the study can be found in Appendix E. The 
participants were randomly assigned into a placebo (control) or treatment group 
on day one of the study. Those assigned to the treatment group consumed 8 
ounces of 100% tart cherry juice daily for 4 weeks, followed by a 4-week washout 
period, and then consumed 8 ounces of a non-anthocyanin containing placebo 
beverage similar in calorie and carbohydrate content for 4 weeks. Subjects 
initially assigned to the placebo (control) group underwent the same protocol but 
consumed the cherry and placebo beverages in the reverse order. All participants 
were required to abstain from the consumption of foods that are considered rich 
sources of anthocyanins over the 12-week study period. A list of these foods was 
provided to participants (Appendix F).  
A fasting blood draw occurred on Day 1 of the study (baseline) and then 
every 4 weeks thereafter (at the completion of weeks 4, 8, and 12). Subjects were 
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given instructions on completing a dietary record that reflected food intake over a 
24-hour period and were to submit one 24-hour dietary record (Appendix G) for 
each week of the study (4 records at each visit). All participants filled out the 
shortened version of the International Physical Activity Questionnaire (Appendix 
H) at the completion of each 4-week study arm (reflecting the previous 7 days of 
activity prior to each visit). It was assumed that the dietary intake and physical 
activity level reported at each visit reflected the average during the previous study 
arm. Anthropometric and body composition data were collected at each visit 
(blood draw) in addition to blood pressure and pulse measurement.  
Dietary Intervention 
The caloric and carbohydrate content of the tart cherry and placebo 
beverage were very similar, and this was expected to prevent weight differences 
caused by the different dietary interventions (Appendix I). The placebo beverage 
served as the control because it is anthocyanin-free. Information regarding 
placebo preparation and tart cherry juice preparation can be found in Appendix J. 
Tart cherry juice or placebo were provided at the visit preceding each 4-week 
study arm period and participants were provided measuring cups and instructions 
on how to measure and store juices. As a measure of compliance, the subjects 
were expected to return all empty and remaining bottles of juice at the completion 
of each study arm.  
Participants were required to fill out one 24-hr dietary record for each 
week of the study and, on the week of the blood draw, the dietary record reflected 
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consumption on the day prior to the draw. This permitted the assessment of 
dietary changes that may have occurred throughout the study and also enabled the 
tracking of any unexpected blood measurements that were not diet related. The 
dietary records were analyzed by Food Processor Nutrition and Fitness Software 
(ESHA, version 8.5; Salem OR) to determine whether subjects were altering their 
diets and to determine compliance with instructions to drink 8 oz of placebo or 
tart cherry juice and to avoid anthocyanin-rich foods. 
Anthropometric Measurements 
 Anthropometric measurements were obtained at the baseline visit and at 
each visit (blood draw) following the completion of weeks 4, 8, and 12. Height 
was recorded at baseline, and weight, waist circumference (WC), blood pressure, 
and pulse were recorded at baseline and every 4 weeks thereafter. In addition, 
body composition (body fat percentage, fat mass, fat-free mass, and total body 
water) and basal metabolic rate was measured by bioelectrical impedance (BIA) 
using a TBF 300A Tanita Body Composition Analyzer (Tokyo, Japan), and BMI 
was recalculated at each visit (Appendix K). 
Blood Analyses 
 Blood samples were drawn from the antecubital vein by a trained 
phlebotomist at the ASU Polytechnic Campus Health Sciences Center or the ASU 
Tempe Campus Clinical Research Unit at baseline of the study and at the 
completion of weeks 4, 8 and 12. Prior to each blood draw, the participants had 
fasted for at least 8 hours. EDTA-treated whole blood was immediately used to 
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determine ESR by the Westergren method (77) (Appendix L) using the 
FisherBrand Disposable Dispette 2 Blood Sedimentation System (Thermo Fisher 
Scientific, Pittsburgh, PA). Plasma from the blood samples were then separated 
by centrifugation at 4°C and 3,300 rpm for 15 minutes and divided in aliquots 
(derived from serum separator, EDTA, and heparin tubes). The aliquots were 
frozen until a later date when blood lipids, fasting glucose, insulin, hsCRP, IL-6, 
IL-10, TNF-α, and MCP-1 were analyzed. Total cholesterol, triglycerides, LDL-
C, HDL-C, fasting glucose, and hsCRP were measured directly using the COBAS 
C 111 blood chemistry analyzer (Roche Diagnostics, Indianapolis, IN) and 
VLDL-C was calculated as TG/5. Insulin was analyzed using an Immulite 1000 
automated chemiluminescent blood chemistry analyzer (Diagnostic Products 
Corporation, Siemens, Deerfield, IL) according to manufacturer’s instructions 
(78, 79). IL-6, IL-10, TNF-α, and MCP-1 were analyzed by a standard sandwich 
enzyme-linked immunosorbent assay (ELISA) using Single Analyte ELISArray 
kits (SABiosciences Corporation, Bethesda, MD) (Appendix M).  
Statistical Analyses 
 Statistical analysis was conducted using the Statistical Package for Social 
Sciences (SPSS) version 18.0, 2010. All values are expressed as mean ± standard 
deviation (SD). According to sample size calculations based on a study conducted 
by Volek, et al. (80), 15 participants were determined to provide an 80% power to 
detect a 23 mg/dL (30%) reduction in triglycerides at an alpha level of 0.05. The 
sample size for this study was 26. Differences were considered significant at 
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P<0.05. A histogram and Shapiro-Wilk’s test were used to test the variables for 
normality, and the following data were logarithmically transformed to achieve a 
normal distribution: CRP, IL-6, IL-10, Insulin, and HOMA. The non-parametric 
data for BMI was inversely transformed to achieve a normal distribution. 
Anthropometric, inflammatory, and plasma lipid values were subsequently 
analyzed using two-way analysis of variance (ANOVA) with repeated measures. 
Each ANOVA test assessed data by group (treatment) and by time (pre/post) to 
determine an interaction effect. Dietary and physical activity data from individual 
treatment groups were compared with the respective controls using paired-
samples t-tests, and data determined to be non-parametric were analyzed via the 






Tart Cherry Juice Composition
Tart cherry juice was used as the treatment intervention in this study 
because it is a significant source of anthocyanins. HPLC was used to establish the 
anthocyanin profile of 100% tart cherry 
predominant anthocyanin pigment in tart cherries, cyanidin
is represented by the peak at 12.026 minutes. Other prominent peaks include those 
at 13.516 minutes, 13.985 minutes, and 16.946 minutes, which correspond to 
cyanidin-3-glucoside, cyani
additional anthocyanins present in tart cherry juice. The peak at 19.595 minutes 
could not be identified. 






juice, which appears in Figure 6. The 
-3-glucosylrutinoside, 
din-3-rutinoside, and peonidin-3-rutinoside, three 
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The total polyphenol concentration of the tart cherry juice and placebo 
beverages were each determined by the Folin-Ciocalteu method, and tart cherry 
juice was demonstrated to contain a significantly higher concentration of 
phenolics (p < 0.05) than the placebo (Figure 7). 
 
 
Figure 7. Total phenolics of the placebo and treatment beverages as determined 
by the Folin-Ciocalteu method. *Statistical significance p < 0.05. 
 
Participant Characteristics  
Although 36 individuals initially enrolled in this study, 26 participants 
completed it in its entirety, including 8 males and 18 females. Of the ten 
participants that dropped out, 2 were lost to follow-up and one participant 
dropped out for each of the following reasons: time constraints, feeling 
mistreated, disliking the taste of the juice, weight gain that was attributed to the 
juice, hospitalization for unrelated issues, a broken foot, an adverse reaction 
subsequent to placebo consumption, and heartburn following juice consumption. 
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Table 3 portrays the participant characteristics at study baseline along with the 
corresponding reference ranges. Based upon BMI values, 14 participants were 
categorized as overweight and 12 as obese. The mean age was 41 years, ranging 
from 22 to 61, and the mean BMI was 31.3 ± 6.3 kg/m2, ranging from 25.0 to 51.3 
kg/m2. 
Anthropometrics  
Anthropometric measurements were recorded at baseline and following 
weeks 4, 8, and 12. The effects of time and treatment on BMI, body fat 
percentage, and WC were evaluated by two-way repeated measures ANOVAs 
(Table 4). There were no significant interaction effects (p > 0.05) for BMI, body 
fat percentage, or WC. There was a statistically significant main effect of 
treatment for WC (p < 0.05), as the placebo measurements were slightly higher 
than the tart cherry measurements, and there was also a statistically significant 
effect of time on BMI (p < 0.05), as the post-treatment values were higher than 
the baseline values following both the placebo and cherry interventions. However, 
there was no significant change in BMI, body fat percentage, or WC when 
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TABLE 3 





      n(m/f) 26 (8/18) 
      Age, yr 41  ±  11 
      BMI, kg/m2 31.3  ±  6.3 
Body fat, kg/m2 37.11 ± 9.99 
Biomarker 
      Total cholesterol, mg/dL < 200 191.6  ±  40.4 
      LDL cholesterol, mg/dL < 100 107.7  ±  29.8   
      VLDL cholesterol, mg/dL < 30 28.76  ±  27.3 
      HDL cholesterol, mg/dL ≥ 402 42.1  ±  12.0 
      Triglycerides, mg/dL < 150 143.8  ±  136.5 
      TG/HDL CVD risk ratio < 3 4.25  ±  6.23 
      TC/HDL CVD risk ratio < 4 4.97  ±  2.21 
      LDL/HDL CVD risk ratio < 3 2.76  ±  1.10 
      Fasting blood glucose, mg/dL < 100  92.7  ±  7.03 
      Insulin, µU/mL 5.0 - 20.0 12.95  ±  6.98 
      QUICKI3 ≥ 0.312 0.336  ±  0.035 
      HOMA3 < 4 2.986  ±  1.651 
      CRP, mg/L < 3 3.75  ±  3.99 
      ESR mm/h 0 – 306 18.25  ±  10.75 
      IL-64, pg/mL 0 - 5.0 93.98  ±  111.64 
      IL-105, pg/mL 1.3 - 15.6 38.04  ±  25.16 
      MCP-1, pg/mL 163 - 438 242.92  ±  161.09 
      TNF-α, pg/mL 0 - 16.6 N/A7 
1
 Values are mean ± SD     
2
 Men: ≥ 40 mg/dL 
  Women: ≥ 50 mg/dL 
3,4,5
 Values are based on n = 25, n =14, and n = 4 due to data being below the assay 
detection limits 
6
 Men: ≤ 50 yr: 0 - 15 mm/h, > 50 yr: 0 -20 mm/h 
  Women: ≤ 50 yr: 0 - 20 mm/h, > 50 yr: 0 – 30 
mm/h 
7
 Below limit of detection for assay 
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TABLE 4 
Effect of cherry and placebo interventions on anthropometrics1 
Placebo Cherry 
Variable Pre Post Pre Post 
 BMI 2, kg/m2 31.4 ± 6.4 31.6 ± 6.5a 31.3 ± 6.4 31.4 ± 6.6a 
 Body Fat, % 38.2 ± 8.2 38.5 ± 8.3 38.7 ± 8.4 38.6 ± 8.1 
 WC, cm 99.3 ± 14 99.1 ± 14   98.6 ± 14.2b 98.6 ± 14b 
     
1
 Data analyzed using two-way repeated measures ANOVA. Values are 
mean ± SD, n = 26. No significant difference for the interaction (time and 
treatment) or main effect of treatment. aMain effect of time was significant at 
P < 0.05. bMain effect of treatment was significant at P < 0.05. 
     
2
 Data were inversely transformed (1/variable) to achieve normality; values 
reported untransformed, mean ± SD. 
 
Dietary Intake 
One 24-hour food record was submitted at baseline and for each week of 
the study period (13 total). The average daily amount of each nutrient consumed 
during the placebo and cherry intervention is shown in Table 5. Though their diets 
were uncontrolled, subjects were asked to maintain their usual intakes throughout 
the study to maintain their original body weight, as fluctuations could confound 
results. Paired-samples t-tests were conducted to compare nutrient consumption 
between the treatment group (cherry) vs. the control group (placebo). 
Although no significant difference (p > 0.05) in the consumption of 
energy, carbohydrate, sugar, total fat, polyunsaturated fat, saturated fat, soluble 
fiber, or omega-3 fatty acids occurred between the placebo and treatment 
interventions, a trend toward significance (0.05 < p ≤ 0.10) was observed for 
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protein and monounsaturated fat intake, which were slightly higher during the tart 
cherry juice intervention compared to the placebo intervention (90 ± 40 and 17.9 
± 7.4 g/d vs. 83 ± 35 and 15.5 ± 7.4 g/d, respectively). In addition, the 
consumption of trans fat was significantly higher (p < 0.05) during the tart cherry 
intervention compared to the placebo intervention (0.47 ± 0.61 g/d vs. 0.22 ± 0.38 
g/d) (Figure 8). 
TABLE 5 
Nutrient composition during cherry and placebo interventions1 
Nutrient Placebo Cherry 
 Energy, kcal/d 2017 ± 531 2052 ± 551 
 Protein2, g/d 83 ± 35 90 ± 40b 
 Carbohydrate, g/d 258 ± 68 259 ± 69 
     Sugar, g/d 114 ± 51 107 ± 55 
 Total fat2, g/d 72 ± 30 74 ± 24 
     Monounsaturated fat, g/d 15.5 ± 7.4 17.9 ± 7.4b 
     Polyunsaturated fat2, g/d 10.6 ± 5.7 9.8 ± 6.5 
     Saturated fat2, g/d 21.9 ± 12.3 24.7 ± 10 
     Trans fat2, g/d 0.22 ± 0.38 0.47 ± 0.61a 
 Total fiber2, g/d 19.0 ± 7.5 19.4 ± 6.1 
 Soluble fiber, g/d 1.49 ± 0.84 1.39 ± 0.62 
 n-3 fatty acids2, g/d 0.96 ± 0.67 0.88 ± 0.69 
     
1
 Data analyzed using paired t-tests. Values are mean ± SD, n = 
25. aSignificance was observed at P < 0.05; Trend toward 
significance was observed at bP 0.1 ≤ P > 0.05. 
     
2
 Wilcoxin signed rank test was used when data were determined 
to be abnormal. 
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Figure 8. Trans fat intake was significantly higher during the cherry intervention 
as compared to the placebo intervention. * Statistical significance p ≤ 0.05. 
 
Physical Activity  
The average physical activity level of each participant was accounted for 
via the collection of the IPAQ questionnaire at the end of each study arm, with 
activity being expressed as the metabolic equivalent of tasks (METs). The number 
of METs performed is an expression of the energy cost associated with physical 
activity, and the average MET-minutes/week expended by subjects during the tart 
cherry juice and placebo intervention is displayed in Table 6. There was no 
significant difference (p > 0.05) in MET-minutes/week between the treatment and 
placebo arms, demonstrating that participant physical activity levels remained 
relatively constant.  
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TABLE 6 
Physical activity during cherry and placebo interventions1 
Physical Activity Placebo Cherry 
 MET-minutes/week2 2193.16 ± 2023.58 2256.35 ± 2496.66 
     
1
 Data analyzed using paired t-tests. Values are mean ± SD, n = 25.  
     
2
 Wilcoxin signed rank test was used when data were determined to be 
abnormal. 
 
Lipids and CVD Risk Ratios  
Lipid samples from venous blood draws were obtained at baseline and 
following weeks 4, 8, and 12. The effects of time and treatment on total 
cholesterol, LDL-C, VLDL-C, HDL-C, and triglycerides were evaluated by two-
way repeated measures ANOVAs (Table 7).  
TABLE 7 
Effect of cherry and placebo interventions on Plasma Lipids1 
Placebo Cherry 
Plasma lipids, mg/dL Pre Post Pre Post 
 Total cholesterol 192 ± 44 196 ± 43a 187 ± 33 196± 35a 
 LDL-C 111 ± 32 113 ± 31a 112 ± 30 120 ± 31a 
 VLDL-C 28 ± 28 32 ± 43 26 ± 14 26 ± 15 
 HDL-C2 42 ± 10 42 ± 10 42 ± 8 43 ± 7 
 Triglycerides 140 ± 137 161 ± 216 129 ± 68 128 ± 74 
     
1
 Data analyzed using two-way repeated measures ANOVA. Values are 
mean ± SD, n = 26. No significant difference for the interaction (time and 
treatment) or main effect of treatment. aMain effect of time was significant at P 
< 0.05. 
     
2
 Normality was achieved following the removal of one outlier; Therefore, 
values are based on n = 25, mean ± SD. 
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No significant interaction effects (p > 0.05) or treatment effects were 
observed for any of these measurements, although there was a statistically 
significant effect of time (p < 0.05) on total cholesterol and LDL-C, as the post-
intervention values were higher than the corresponding baseline values following 
both the placebo and cherry arms. However, there was no significant change in 
total cholesterol, LDL-C, VLDL-C, HDL-C, or triglycerides when comparing the 
two treatment groups over time. CVD risk ratios were calculated based on lipid 
values obtained from each blood draw (Table 8), and these values were also 
analyzed via two-way repeated measures ANOVAs. There were no significant 
interaction effects between time and treatment (p > 0.05) or for the main effects of 
time and treatment for the TG/HDL, TC/HDL, or LDL/HDL risk ratios, 
demonstrating that each ratio remained relatively stable between treatment groups 
over time. 
TABLE 8 
Effect of cherry and placebo interventions on CVD risk ratios1 
Placebo Cherry 
CVD risk ratio Pre Post Pre Post 
 TG/HDL 4.09 ± 6.28 5.01 ± 10.14 3.29 ± 2.20 3.20 ± 2.45 
 TC/HDL 4.79 ± 2.22 4.91 ± 2.40 4.53 ± 1.38 4.62 ± 1.39 
 LDL/HDL 2.73 ± 1.07 2.76 ± 1.01 2.73 ± 1.05 2.85 ± 1.03 
     
1
 Data analyzed using two-way repeated measures ANOVA. Values are 
mean ± SD, n = 26. No significant difference for the interaction (time and 
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Glucose, Insulin, and Insulin Sensitivity  
Fasting glucose samples obtained from venous blood draws occurring at 
baseline and following weeks 4, 8, and 12 were assessed by two-way repeated 
measures ANOVAs (Table 9), and no significant interaction effect (p > 0/05) or 
main effect of treatment was reported. The main effect of time was determined to 
be significant (p < 0.05) as the post-intervention measurements were higher than 
the corresponding baseline measurements subsequent to both the tart cherry juice 
and placebo arms. However, there was no significant change in fasting glucose 
when comparing the two treatment groups over time. 
TABLE 9 
Effect of cherry and placebo interventions on fasting glucose1 
Placebo Cherry 
Variable Pre Post Pre Post 
Glucose, mg/dL 93.6 ± 7.2 97.5 ± 10.8a 92.6 ± 7.3 96.0 ± 11.0a 
     
1
 Data analyzed using two-way repeated measures ANOVA. Values are 
mean ± SD, n = 26. No significant difference for the interaction (time and 
treatment) or main effect of treatment. aMain effect of time was significant at P 
< 0.05. 
 
Fasting insulin was also measured at each of the 4 blood draws and was 
used along with fasting glucose measurements to calculate the quantitative 
insulin-sensitivity check index (QUICKI) and the homeostasis model assessment 
(HOMA), which are both indices of insulin sensitivity. Fasting insulin, QUICKI, 
and HOMA were each analyzed via two-way repeated measures ANOVA (Table 
10) and no significant interaction effect or main effect of time or treatment was 
observed (p > 0.05). Although no significant alteration in fasting insulin or the 
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indices of insulin sensitivity occurred between the two treatment groups over 
time, the baseline values obtained from the QUICKI and HOMA equations 
indicate that the participants of this study are approaching insulin resistance and 
the associated pre-diabetic state. 
TABLE 10 
Effect of cherry and placebo interventions on insulin and markers of insulin 
sensitivity1 
Placebo Cherry 
Variable Pre Post Pre Post 
 Insulin2 13.25 ± 9.75 15.64 ± 9.96 17.07 ± 12.61 19.72 ± 19.75 
 HOMA2 3.125 ± 2.44 3.913 ± 2.81 3.922 ± 2.76 4.952 ± 6.05 
 
QUICKI 0.337 ± 0.03 0.328 ± 0.04 0.330 ± 0.04 0.320 ± 0.032 
     
1
 Data analyzed using two-way repeated measures ANOVA. Values are 
mean ± SD, n = 24. No significant difference for the interaction (time and 
treatment) or main effects of time and treatment.  
     
2
 Data were logarithmically transformed (log variable) to achieve 
normality; values reported untransformed, mean ± SD. 
 
Inflammatory Cytokines and Biomarkers  
In addition to blood lipids, fasting glucose, and fasting insulin, cytokines 
and inflammatory biomarkers were also measured using samples obtained from 
venous blood draws occurring at baseline and following each 4-week placebo and 
tart cherry juice intervention. The cytokines evaluated included IL-6, IL-10, and 
TNF-α, and the inflammatory biomarkers assessed included CRP, ESR, and 
MCP-1. Of 26 subjects tested, only 14 produced samples with IL-6 levels above 
the detection limit of the assay and only 4 provided samples having IL-10 levels 
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above the assay detection limit. No samples were determined to contain TNF-α 
concentrations above the detection limit of the assay, and therefore this cytokine 
was eliminated from analysis. The small number of viable measurements obtained 
for IL-6 and IL-10 were evaluated using a two-way ANOVA (Table 11) to 
compare the effect of time and intervention on each variable, and the interaction 
effect was determined to be insignificant for each (p > 0.05). In addition, no 
significant difference for the main effects of time and treatment were observed (p 
> 0.05). 
TABLE 11 
Effect of cherry and placebo interventions on cytokines1 
Placebo Cherry 
Cytokine, 
pg/mL Pre Post  Pre Post 
IL-6 2, 3 78.6 ± 113.6 230.8 ± 394.7 89.3 ± 138.3 197.9 ± 264.3 
IL-10 2, 4 34.6 ± 25.0 47.1 ± 39.8 24.9 ± 19.9 20.1 ± 16.5 
TNF-α 5 N/A N/A   N/A N/A 
     
1
 Data analyzed using two-way repeated measures ANOVA. Values are 
mean ± SD. No significant difference for the interaction (time and treatment) 
or main effects of time and treatment.  
     
2
 Data were logarithmically transformed (log variable) to achieve 
normality; values reported untransformed, mean ± SD. 
     
3 Values are based on n = 14 due to samples being below the assay 
detection limit 
     
4 Values are based on n = 4 due to samples being below the assay 
detection limit 
     
5
 All samples below assay detection limit 
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The inflammatory biomarkers CRP, ESR, and MCP-1 were also assessed 
via two-way ANOVA, and the values preceding and subsequent to each 4-week 
intervention are displayed in Table 12. Analysis revealed no significant difference 
(p > 0.05) for the interaction (time and treatment) effect or main effects of time 
and treatment on CRP, ESR, or MCP-1 levels, demonstrating that statistically 
there was no appreciable change in the concentrations of these inflammatory 
biomarkers between the tart cherry juice and placebo intervention over time.    
TABLE 12 
Effect of cherry and placebo interventions on inflammatory biomarkers1 
Placebo Cherry 
Marker Pre Post Pre Post 
CRP 2, ng/mL 4.04 ± 4.30 3.83 ± 3.90 4.93 ± 7.10 3.97 ± 4.08 
ESR, mm/h 19.6 ± 13.2 21.9 ± 13.7 20.2 ± 11.2 20.9 ± 12.2 
 MCP-1, pg/mL 250 ± 164 276 ± 131   287 ± 216 269 ± 146 
     
1
 Data analyzed using two-way repeated measures ANOVA. Values are 
mean ± SD, n = 26. No significant difference for the interaction (time and 
treatment) or main effects of time and treatment.  
     
2
 Data were logarithmically transformed (log variable) to achieve normality; 
values reported untransformed, mean ± SD. 
 
Although the change in MCP-1 between the pre and post-cherry and pre 
and post-placebo interventions was not determined to be statistically significant 
via two-way ANOVA, MCP-1 increased by more than 26 pg/mL after the placebo 
intervention and decreased by more than 18 pg/mL after the tart cherry 
intervention.  
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Chapter 5 
Discussion 
 The purpose of this study was to assess the effectiveness of 100% tart 
cherry juice in improving biomarkers of dyslipidemia and inflammation in 
overweight and obese subjects. It was hypothesized that the consumption of 8 oz 
of cherry juice daily over a 4-week period would result in a measurable 
improvement in both the lipid and inflammatory profiles of study participants 
without disrupting glucose homeostasis. Data analysis comparing the placebo and 
treatment interventions over time did not show a statistically significant 
improvement in any of the lipid or inflammatory biomarkers. However, there was 
a statistically significant increase in dietary trans fat during the treatment arm 
compared to the placebo arm and, although unlikely, it is possible that this 
alteration may have confounded study results.   
 A specific aim of this study was to evaluate the effect of tart cherry juice 
consumption on lipid parameters, including total cholesterol, LDL-C, VLDL-C, 
HDL-C, TG and the calculated CVD risk ratios TC/HDL, TG/HDL, and 
LDL/HDL. The outcome of this study, demonstrating no significant effect of 
cherry juice on lipid biomarkers and risk ratios, is both supported and refuted by 
the literature, as previous research studies conducted using cherries have found 
conflicting results. Two previously cited studies conducted by Seymour, et al. (12, 
13) reported a significant decrease in total cholesterol and triglycerides in Dahl-
SS and Zucker fatty rats following 90 days of freeze-dried tart cherry 
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consumption. These findings were not in agreement with the results of this study, 
and the different outcomes may have derived from differences in the study 
designs and subject populations, as 90 days of treatment may be more likely to 
elicit a significant alteration in blood lipids, and Zucker and Dahl-SS rats display 
an extremely high affinity for developing characteristics of metabolic syndrome 
and may therefore be more susceptible to a treatment response. Improvement 
observed in the lipid profile of the fatty Zucker rats may also have been a function 
of the significant weight loss that was observed over the intervention period. In 
addition, rats and human have different metabolic characteristics, making results 
from rodent models potentially less applicable to humans. Rats absorb less dietary 
cholesterol than humans, have significantly higher HDL-C levels, and also lack 
CETP, making them resistant to atherogenesis and a poor experimental model for 
use in lipid-related research (81). 
 Previous research studies analyzing the effect of cherry consumption on 
lipid parameters in humans have reported a diverse array of outcomes, which may 
also be partially attributed to differences in the study designs and subject 
populations employed between interventions. The lack of significant effect 
observed on the blood lipid profile in this study was in agreement with results 
reported by Kelley et al. (14) following 28 days of Bing sweet cherry 
consumption, where no changes were measured in total cholesterol, LDL-C, 
VLDL-C, HDL-C, TG, or the TC/HDL CVD risk ratio. The study conducted by 
Ataie-Jafari et al. (70) evaluating the effect of 3 TBSP of tart cherry juice 
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concentrate daily over a period of 6 weeks on blood lipids in 19 type 2 diabetic 
Iranian women also reported no effect on blood lipid concentrations. However, a 
significant decrease was detected in total cholesterol and LDL-C when 
considering only hyperlipidemic subjects. Alternatively, in the pilot study by 
Martin et al. (76), no effect was observed on concentrations of total cholesterol, 
LDL-C, VLDL-C, or HDL-C following the daily consumption of 8 oz of tart 
cherry juice for 4 weeks, but a significant reduction was observed in TG.  
Potential explanations for discrepancies in the outcomes of this study and 
the Ataie-Jafari et al. study (70) might be based on differences in subject lipid 
profiles. The subject population used in this study possessed baseline lipid values 
within the healthy reference ranges, with the exception of LDL-C, which was only 
slightly elevated (107.7 mg/dL) and considered near optimal according to the 
NCEP (23). The population that experienced a significant reduction in total 
cholesterol and LDL-C in the Ataie-Jafari et al. study was hyperlipidemic, having 
total cholesterol and LDL-C pre-treatment values of 213.9 and 118.4 mg/dL, 
respectively, and demonstrated more susceptibility to the cherry juice intervention 
than the population displaying healthy levels. Pre-treatment total cholesterol and 
LDL-C values in this study were 187.3 and 111.5 mg/dL, respectively, leaving 
less room for improvement. Another factor that may have contributed to 
significance in the Ataie-Jafari et al. study may be attributed to the research 
design, as the treatment duration was longer (6 weeks vs. 4 weeks) and the daily 
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dosage of concentrated juice was slightly higher (3 TBSP vs. 2.66 TBSP) than in 
this study.   
Similar to the Ataie-Jafari et al. study (70), a possible explanation for 
different outcomes between this study and that of Martin et al. (76) in respect to 
TG may also be attributed to disparities in the blood lipid levels of each subject 
population, as Martin et al. reported much higher pre-treatment TG values (147 
vs. 129 mg/dL). In addition, Martin et al. used 10 participants, which may have 
enabled TG outcomes to become skewed. No significance was observed in respect 
to total cholesterol, LDL-C, VLDL-C, and HDL-C, which were generally within 
the optimal reference ranges and were each very similar to the values of this 
study, thus contributing to evidence that higher serum lipids may be necessary to 
achieve significant changes. 
Only one of these studies reported significance in regard to the TC/HDL, 
TG/HDL, or LDL/HDL CVD risk ratios (non-significance was reported in 
TC/HDL by Kelley et al. (14)) , but achieving significance in these parameters is 
dependent upon alterations in individual TC, LDL-C, HDL-C, or TG 
concentrations. This study did not demonstrate statistical differences in any of the 
ratios, which is not surprising due to the lack of change observed in the lipid 
biomarkers. Had participants displayed sufficient hyperlipidemia, possessing lipid 
values and CVD risk ratios well above normal reference ranges, evidence from 
previous research suggests that there would have been more room for alteration 
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and significance may have been derived from increased susceptibility to a cherry 
intervention.   
A second aim of this study was to evaluate the effects of tart cherry juice 
on the inflammatory profile. Analyses of IL-6, hsCRP, MCP-1, ESR, and IL-10, 
showed no statistically significant improvement following the administration of 
treatment compared to placebo over time. Similar to the contradictory outcomes 
derived from studies analyzing the effect of a cherry intervention on blood lipid 
parameters, previous research evaluating the effects of cherries and anthocyanin-
rich fruit juices on biomarkers of inflammation have yielded inconsistent results.  
Contrary to the lack of effect observed on IL-6 levels in this study, the 
Seymour et al. study (13) conducted in Zucker fatty rats demonstrated a 
significant reduction in retroperitoneal and plasma IL-6 concentrations, as well as 
a significant decline in IL-6 mRNA production following consumption of freeze-
dried whole tart cherry powder. Contrasting results may have been a function of 
the significant total and retroperitoneal fat loss that occurred during the treatment 
intervention of the Seymour et al study as opposed to the lack of weight-loss 
observed in this study. Adipocytes generate approximately 1/3 of plasma IL-6, 
and concentrations have been shown to positively correlate with fat mass (82). In 
addition, visceral adipose depots express more IL-6 than other areas due to 
increased macrophage infiltration (29), making the significant retroperitoneal fat 
loss observed in the Zucker rats a likely explanation for the corresponding IL-6 
reduction. Other previously described factors that may explain the different 
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outcomes achieved between these studies are the much longer intervention period 
(90 days) and the higher dosage of anthocyanins provided in the Seymour et al. 
study, the high affinity for obesity and systemic inflammation that may increase 
treatment susceptibility in Zucker rats, and the different metabolic properties of 
rats and humans that limit applicability of research outcomes obtained using 
rodent-models to humans.   
  Alternatively, studies analyzing the effect of a cherry intervention on IL-6 
concentrations in humans have supported the findings of this study, as no 
statistically significant effects on IL-6 were reported by Kelley et al. (14) or 
Martin et al. (75). However, research using anthocyanin-rich fruit juice as a 
treatment intervention has derived conflicting results in respect to inflammatory 
biomarkers and IL-6. While the phenolic profile between individual fruits may 
differ somewhat and produce slight variations in anti-oxidant and anti-
inflammatory capacities, blueberries and bilberries are similar to cherries in that 
they are high in anthocyanin content. Although making direct comparisons 
between the effects of different fruits on the inflammatory profile has its 
limitations, comparing outcomes of studies using fruit-juice derived interventions 
has the benefit of a similar food matrix, unlike comparisons made between juice 
and whole fruits or purified anthocyanin-rich extracts.  
 Basu et al. (83) conducted a randomized placebo-controlled study 
evaluating the effect of daily blueberry juice consumption (equivalent to 350 g of 
fresh blueberries) on inflammatory biomarkers over a 8-wk period in 48 obese 
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subjects with metabolic syndrome, and Karlsen et al. (84) conducted a similar 
randomized placebo-controlled study to determine the effect of 330 mL of daily 
bilberry juice consumption on inflammatory parameters over a 4-wk period in 62 
participants at elevated risk of CVD. These studies obtained contradictory results, 
as Karlsen et al. demonstrated a significant increase in IL-6 levels and Basu et al 
did not. Results of studies analyzing the effect of cherries and anthocyanin-rich 
fruit juices on other inflammatory biomarkers, such as CRP, also derived 
conflicting results, as Kelley et al. observed a significant 25% reduction in CRP 
(14), Martin et al. observed a non-significant 16% increase in levels (75), Karlsen 
et al. reported a significant reduction in levels (84), and Basu et al. reported no 
significant change in CRP levels (83). Similar to findings by Martin et al and 
Basu et al., no statistically significant reduction in CRP concentration was 
demonstrated in this study. However, a 19.5% decline in CRP was observed 
subsequent to cherry juice consumption compared to a 5.2% decline following 
placebo, and it is likely that significance was not achieved partially due to 
insufficient power conferred by large standard deviations, ranging from 3.8 to 7.1 
ng/mL. 
There are several potential explanations for the different outcomes 
achieved by this study and those reported by Kelley et al. (14) in respect to CRP 
and Karlsen et al. (84) in respect to both CRP and IL-6. The whole cherries used 
by Kelley et al. may have had more anthocyanins and a higher capacity to reduce 
CRP than the cherry juice used in this study, as the skin of whole cherries are 
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reported to contain the majority of the anthocyanins with the fruit (55, 72). 
Similarly, the form of intervention used by Karlsen et al. may have conferred an 
increased capacity to reduce CRP and IL-6 than that used in this study, as the 
phenolic profiles and content of bilberries and cherries differ. Although some 
cherry varieties are reported to contain more anthocyanins than bilberries (1.3 – 
6.8 mg/g vs. 4.5 mg/g), cherries contain far fewer total phenolics than bilberries 
(2.4 – 8.8 mg/g depending on variety vs. 10.4 mg/g) (85). The higher amount of 
total phenolics present in bilberries, or an increased ability of anthocyanins to 
synergistically function with these additional polyphenols, may have caused or 
contributed to the significant reduction observed in CRP and IL-6 in response to 
the bilberry juice intervention as opposed to the tart cherry intervention. In 
addition, the daily dosage of bilberry juice was higher (330 mg/dL or 
approximately 11 oz juice) than the dosage of cherry juice (8 oz), thereby 
potentially conferring a greater effect on CRP and IL-6 levels depending on the 
concentration of each juice. 
Another possible explanation for the different outcomes achieved by this 
study and that of Karlsen et al. (84) in respect to CRP is based on certain 
characteristics of each study population and the ability of these characteristics and 
other exogenous factors to impact CRP levels. CRP has previously been described 
as an acute-phase reactant protein produced by the liver during inflammatory 
processes and other diseases (86), but levels have also been reported to escalate in 
response to a variety of factors, including environmental pollution and irritants, 
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second hand smoke, specific dietary patterns, minor tissue injuries, low levels of 
physical fitness, and the use of estrogen and progesterone containing supplements 
such as birth control and hormone replacement therapies (87). Of the 26 
participants who completed this study, 18 were female and of these 4 reported 
taking some form of contraceptive or estrogen supplement, which may have 
driven CRP levels up slightly and reduced the potential lowering effect conferred 
by tart cherry juice. In contrast, the female participants in the Karlsen et al. study 
were at least 12-months post-menopausal and therefore not taking any form of 
birth control, and were also not engaging in hormone replacement therapy. Had 
participants in this study not been permitted to take estrogen and progesterone 
containing supplements, perhaps CRP levels would have been more responsive to 
treatment and significance may have been reached. Kelley et al. (14) also noted 
significant reductions in CRP but did not publish data regarding the use of 
estrogen-containing supplements, preventing consideration of this factor during 
the interpretation of study results. 
The population from which subjects were selected for this study was 
assumed to be high risk for low-grade inflammation due to classification as 
overweight or obese based on BMI calculations and the association of adipose 
tissue with elevated cytokines. High baseline CRP, IL-6, and IL-10 concentrations 
substantiated this assumption, although levels of MCP-1 and ESR were within the 
normal reference ranges. Only 14 of the 26 subjects had IL-6 values at the 
minimal level of detection for the assay, and within these 14 participants the mean 
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concentration was 94 ± 111.6 pg/mL. Even when including the 12 additional 
subjects by substituting in the minimum value possible for each, IL-6 was still 
above the normal reference range. Similarly, baseline CRP levels were also above 
normal. The high corresponding levels of IL-6 and CRP make sense when 
considering the inflammatory process, as CRP synthesis and release from 
hepatocytes is primarily dependent upon circulating levels of IL-6. In turn, CRP 
has been demonstrated to contribute to the cyclic nature of inflammation by 
increasing IL-6 production by monocytes (88). Because high baseline levels of 
inflammatory biomarkers provide substantial room for improvement, it is 
interesting that no significant reduction was observed in IL-6 or CRP 
concentrations. Therefore, levels too low for improvement via treatment is not a 
viable explanation for lack of effect. 
Very few studies have reported the effect of a cherry or anthocyanin-rich 
fruit juice intervention on levels of MCP-1, IL-10, or ESR, but those that have 
done so generally agreed with the results of this study, demonstrating no 
statistically significant reduction in these biomarkers. As an extremely potent 
chemokine, MCP-1 mediates inflammation and atherogenesis by attracting 
monocytes to inflammatory lesions and helping to initiate their endothelial 
binding (89). Not only does MCP-1 function to influence downstream pathways 
and exacerbate the inflammatory response by attracting chemical mediators to 
sites of damage, but its synthesis and release is in turn influenced by the 
concentration of other cytokines and has been associated with high CRP levels 
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(90). It is interesting to note that Kelley et al. (14) and Karlsen et al. (84) observed 
no effect on concentrations of MCP-1, even though they observed significant 
reductions in other inflammatory biomarkers, such as CRP. It is also interesting 
that in this study, baseline levels of CRP and IL-6 were above the normal 
reference ranges, yet no correlation was seen with MCP-1 values, as these were 
within the normal reference range.  
Although cherry juice consumption did not result in a statistically 
significant reduction of MCP-1 in this study, a non-significant reduction of 6.3% 
was observed following the treatment arm compared to a 10.4% increase 
following the placebo arm. As with CRP, this non-significant result may be 
partially attributed to insufficient power conferred by the large standard 
deviations around the mean values, which ranged from 131 to 216 pg/mL. 
Nonetheless, non-significance in MCP-1 is generally consistent with the findings 
from previous studies, including those by Kelley et al. (14) and Karlsen et al. (84). 
Martin et al. (75) also did not detect a significant reduction in MCP-1 when 
comparing the treatment and placebo arms of the crossover study, but a 
significant decrease was observed when subjects were grouped by study beverage 
(n = 4). This may indicate the need for a longer washout period. Additionally, 
conclusions based on stratification resulting in small sample sizes are more prone 
to a type 1 systematic error.  
Although Martin et al. (75) also noted a significant difference in ESR 
when comparing the first arm only, no significance was observed in ESR across 
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both intervention arms, concurring with the results of this study. ESR measures 
the rate at which RBCs settle in the blood, and inflammatory states elevate blood 
protein causing RBCs to descend more quickly over a given period of time. 
Therefore, this inflammatory parameter is non-specific in nature and, similar to 
CRP, may be influenced by a variety of exogenous factors, such as menstruation, 
anemia, oral contraceptives, vitamin A, and certain pharmaceutical drugs (86). As 
previously noted, 4 of the participants in this study reported taking some form of 
oral contraceptive, and 2 of the participants reported experiencing periodic 
episodes of anemia. Theoretically, if the literature were to have supported the 
effectiveness of tart cherry juice in decreasing ESR, one explanation for the non-
significance noted in this study may have been a reduced capacity of the juice to 
elicit significant lowering effects due to ESR elevation by participant 
contraceptive use and anemia. Other explanations might include limited 
susceptibility to a significant treatment response conferred by the normal baseline 
ESR values in this study, or the inability of ESR to respond due to a lack of 
necessary time and sensitivity, as ESR is an extremely slow responder and less 
sensitive than other indicators of inflammation (86). 
Just as no significant alterations were observed in any of the inflammatory 
parameters IL-6, CRP, MCP-1, and ESR, no change was observed in IL-10 
concentrations when comparing the tart cherry juice and placebo interventions 
over time. Kelly et al. (14), Karlsen et al. (84), and Martin et al. (75) corroborated 
this finding, each determining their anthocyanin-rich intervention to have no 
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effect on IL-10 levels. IL-10 is an anti-inflammatory cytokine that typically 
elevates and declines along with levels of pro-inflammatory cytokines, being up-
regulated in response to increased inflammation in order to down-regulate it (91). 
Therefore, because no statistically significant changes were observed in the other 
inflammatory markers in this study, it is not unexpected that no significant change 
was elicited in IL-10. In addition, because baseline CRP and IL-6 levels were 
determined to be high, it makes sense that baseline IL-10 concentrations were also 
elevated. 
 This study was based on the hypothesis that tart cherry juice consumption 
would improve biomarkers of dyslipidemia and inflammation without disrupting 
glucose homeostasis. Fasting glucose, insulin, and the insulin-sensitivity indices 
HOMA and QUICKI were expected to remain constant throughout the study, as 
demonstrated by numerous published studies evaluating the effect of an 
anthocyanin-rich intervention in humans (14, 70, 83, 92, 93, 93, 94). As 
anticipated, this study noted no significant alteration in fasting glucose, insulin, or 
the insulin-sensitivity indices and is consistent with previous research. 
 WC, BMI, and body fat percentage were measured throughout the study to 
monitor any changes in weight or adiposity that might confound study results. 
None of these variables significantly changed throughout the 12-week study 
period as expected, demonstrating that energy expenditure, energy intake, and 
macronutrient consumption remained relatively consistent during each arm of the 
intervention. No statistically significant alteration was observed in physical 
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activity level as measured by MET-minutes/week, and there was no significant 
difference between calorie consumption or intake of carbohydrates, sugar, protein, 
total fat, monounsaturated fat, polyunsaturated fat, saturated fat, soluble fiber, or 
omega-3 fatty acids within the placebo and treatment arms. 
 However, the consumption of trans fat was determined to be significantly 
higher during the cherry intervention as compared to the placebo intervention (p < 
0.05), despite subjects being instructed to maintain their usual dietary habits 
throughout the entire study period. The significant difference between trans fat 
intake during the placebo and treatment arms is important because trans fat has 
been reported to have a variety of adverse effects on risk factors for chronic 
disease, including those related to inflammation and dyslipidemia (95). Although 
they occur naturally in small quantities in meat and dairy products, most trans fats 
are produced commercially via the partial hydrogenation of unsaturated oils, 
which renders oils solid at room temperature by converting some of the cis bonds 
to trans bonds (96). The modified physical properties of trans fats makes them 
more desirable for use in the cooking and manufacturing of processed foods, but 
also negatively alters the biological effects of the fats upon consumption (95). A 
meta-analysis examining the effects of trans fats on blood lipids and systemic 
inflammation determined increased trans fat intake to be associated with increased 
total cholesterol, LDL-C, triglycerides, TC/HDL ratio, and decreased HDL-C, as 
well as increased IL-6, CRP, TNF-α, and MCP-1 possibly through effects exerted 
on monocytes and macrophages (95-97). There is also some evidence to suggest 
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that high trans fat consumption may increase post-prandial insulin, glucose, and 
visceral fat accumulation (95). 
 When determining the potential for the significant differences detected in 
trans fat levels between the cherry juice and placebo arms of the study to have a 
confounding effect on results, several issues must be considered. First, the 
potential of these differences to be valid should be explored. Of the 25 
participants who turned in complete dietary data, 64% reported consuming more 
trans fat during the cherry arm than the placebo arm. In addition, there were no 
outliers to potentially skew the mean. Based on the randomized, single-blind, 
placebo-controlled, crossover design of the study, it is perplexing that the subjects 
would randomly increase their trans fat intake by more than twice as much during 
the cherry arm as compared to the placebo, especially when they were instructed 
to maintain their usual dietary habits throughout the entire study. In addition, 
there is no evidence for a biological mechanism to account for this observation, 
such as an increased craving for trans fats conferred by tart cherry juice. 
Alternatively, a behavioral explanation for the significant deviation in intake may 
be more feasible, as several subjects reported disliking the taste of the cherry juice 
and may have been drinking it along with high trans fat-containing comfort foods 
to increase palatability. Another more likely possible explanation would be that 
the variation in levels is spurious, and simply occurred by chance (type 1 
statistical error).  
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 When deliberating the validity of these differences, the weaknesses 
associated with 24-hour food records and the food processor program used to 
analyze nutrient data must each be taken into account. Inaccurate reporting of 
food consumption is a considerable problem across research studies. When 
documenting food intake over a 24-hr period, the most common error made is 
under or over-reporting, which produces serious bias in total energy, 
macronutrient, and micronutrient estimates (98). Approximately 12 to 44% of 
subjects using estimated food intake methods have been demonstrated to 
significantly underestimate consumption, frequently as a result of memory lapses, 
inability to adequately judge portion sizes, and/or embarrassment or shame (98). 
The quality of programs used for entering, analyzing, and quantifying nutrient 
data, as well as the database through which the program derives nutrient 
information, can also affect the validity of the nutrition data obtained. For this 
study, dietary records were analyzed by Food Processor Nutrition and Fitness 
Software (ESHA, version 8.5), which was made available in 2005. The database 
through which the program runs is incomplete in reference to trans fat, which is 
continually being updated as new data becomes available and as new versions are 
released.  Disclosure of trans fat values on manufactured product labels were not 
required until January 1, 2006, and data sources such as the USDA generic data, 
voluntary labeling data, and fast food data are still exempt from this requirement. 
As of 2011, only 50% of the software’s database foods included information for 
trans fat. Because this study used the 2005 software version, the database was 
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significantly more incomplete, seriously calling into question the validity of the 
trans fat values provided.  
 However, if it were assumed that the levels of trans fat derived from the 
Food Processor software were accurate, another factor that would need to be 
explored is biological relevance. In Europe and North America, the average intake 
of trans fat is between 5 and 10 g/day when consuming a typical 2000 kcal diet, or 
between 2% and 4% of total energy intake (95). However, the American Heart 
Association recommends that trans fat be limited to less than 1% of daily energy 
intake, or less than 2 g/day on a 2000 kcal diet (99). Therefore, the levels of trans 
fat reported during both the placebo and cherry intervention arms are well under 
recommendations at 0.22 g and 0.47 g each. This amounts to only 0. 1% and 0.2% 
of subjects’ total daily energy intake and, even though a mere 2% increase in trans 
fat has been associated with a 23% increase in CVD risk (96), the intake during 
both the cherry and placebo interventions are far too low to be considered 
biologically relevant or even significantly different from one another when 
analyzed as total energy intake. 
 Although the actual values reported in this study are likely to be too low 
due to largely incomplete trans fat data provided by the Food Processor database, 
it is possible that the proportion of trans fat consumption occurring during the 
treatment arm compared to the placebo arm is valid. If this is the case, but each of 
the values is actually significantly higher, the differences could be biologically 
relevant and a confounding effect on the inflammatory and blood lipid variables 
   81 
may have occurred. If this had occurred, pro-inflammatory biomarkers and total 
cholesterol, LDL-C, VLDL-C, TG, and the CVD risk ratios may have been driven 
up, and the anti-inflammatory biomarker IL-10 along with HDL-C may have been 
driven down. However, this scenario is unlikely primarily because of the error 
introduced by the Food Processor software combined with that of participant food 
record misreports.   
 Although this study found no evidence to suggest that consuming 8 oz of 
tart cherry juice daily will improve biomarkers of dyslipidemia and inflammation 
in a population of overweight and obese subjects, a target population at greater 
risk may have produced a different set of results. Participants in this study were 
assumed to have high risk for dyslipidemia and inflammation based on high BMI 
and body fat measurements. However, if these inclusion criteria had been set 
higher, such as requiring a minimal BMI of 30.0 or 35.0 kg/m2 and a minimal 
body fat of 30% for men and 35% for women, the subject sample may have been 
hyperlipidemic or demonstrated an even greater level of inflammation and been 
more responsive to treatment. Excluding potential subjects based on the use of 
progesterone and estrogen-containing supplements may also have increased 
treatment response, particularly in respect to CRP and ESR. An attrition rate of 
20% was assumed prior to the study, yet 28% of the participants dropped, 
producing a smaller sample population than planned. Perhaps the implementation 
of higher and more rigorous inclusion criteria combined with the recruitment of a 
larger subject sample may have elevated and tightened the serum lipid and 
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inflammatory characteristics, narrowing the standard deviation in parameter 
values and increasing the potential of measurements to achieve significance. 
Although compliance was determined by the return of empty and remaining 
bottles, it is possible that participants poured juice out instead of drinking it, and 
therefore overall compliance may be unknown. It was also assumed that the self-
reported activity levels provided were correct and that the 24-hr dietary recalls 
accurately reflected dietary intake. Whether reported values and differences in 
trans fat consumption were legitimate or not and whether confounding may have 
occurred is unlikely but subject to conjecture. Clearly, further investigation 
evaluating the effects of a tart cherry juice intervention on biomarkers of 
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Chapter 6 
Conclusions and Applications 
The growing prevalence of chronic disease within the United States and 
globally has become an epidemic, killing millions of people each year. 
Inflammation and dyslipidemia are intimately associated with the etiology of 
many chronic diseases, most notably CVD, which is the leading cause of death in 
America. Studies evaluating the effect of anthocyanin-rich interventions on serum 
lipid and inflammatory profiles have demonstrated beneficial effects. Because tart 
cherries are high in anthocyanins and total phenolics, it was hypothesized that the 
daily consumption of 8 oz of tart cherry juice would significantly improve 
biomarkers of dyslipidemia and inflammation.  
However, data comparing concentrations of total cholesterol, LDL-C, 
VLDL-C, HDL-C, TG and the CVD risk ratios TC/HDL, TG/HDL, and 
LDL/HDL, as well as IL-6, hsCRP, MCP-1, ESR, and IL-10 across time and 
intervention showed no statistically significant changes in any of the markers. 
Possible explanations include a reduced susceptibility to treatment conferred by a 
study cohort possessing lipid and inflammatory values too near normal to be 
significantly altered, the relatively high use of progesterone and estrogen-
containing supplements driving certain inflammatory biomarkers up, and the large 
variation in subject characteristics producing standard deviations too high in many 
variables to show significant alterations. Other possible explanations for the lack 
of effect observed include the unknown compliance of participants regarding juice 
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consumption and the potential of the treatment dose to be too low in anthocyanin 
concentration to elicit a response.  
Another issue that may have influenced the effect of tart cherry juice on 
the blood lipid and inflammatory variables is trans fat consumption. Trans fat 
intake was observed to be significantly higher during the cherry arm as compared 
to the placebo arm (p < 0.05), causing the potential of confounding to be called 
into question. However, this scenario is very unlikely due to the high probability 
that the incomplete Food Processor program database produced inaccurate trans 
fat values.  
Although no significant effects were observed on the lipid and 
inflammatory profiles of the participants drinking tart cherry juice, valuable 
information was obtained that may be useful in establishing future 
recommendations for cherry juice consumption. For example, although the cherry 
juice contained approximately 27 grams of sugar, fasting plasma glucose and 
insulin levels were not significantly affected. In addition, a 1% reduction was 
observed in triglycerides following cherry juice consumption compared to a 14 % 
increase following placebo, even though the cherry juice contained slightly more 
sugar than the placebo beverage. These observations suggest that tart cherry juice 
may be a safe beverage option for those seeking to prevent the development of 
dysglycemia and high triglycerides, and may be a healthy alternative to drinking 
non-anthocyanin containing sugary beverages such as fruit punch. Furthermore, 
although this study does not demonstrate the capacity of tart cherry juice to 
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improve lipid and inflammatory profiles already abnormal or approaching 
abnormal, it is possible that tart cherry juice consumption may be an important 
preventative measure against the development of dyslipidemia, inflammation, and 
chronic diseases associated with such conditions. While important applications 
have been derived from this study, further research is necessary to better 
investigate the impact of tart cherry interventions on biomarkers of dyslipidemia 
and inflammation. 
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Participant ID #: _____________ 
Date: ______________________ 
Inclusion Criteria Check Sheet 
 
1. Generally healthy    Yes  No 
2. Over 18 years of age    Yes  No 
3. Pregnant     Yes  No 
4. Diagnosed with diabetes   Yes  No 
5. Diagnosed with other medical condition or disease such as inflammatory disease 
      Yes  No 
6. Ht:_____Wt: _____Calculated BMI: _______ (completed by investigator >25.0 kg/m2) 
7. % Body Fat _____________ Unknown 
8. Inflammatory condition such as rheumatoid arthritis or gout?      Yes  No 
 If so, are you taking medications for the condition? _______________________ 
9. Take medications and/or supplements?   Yes  No 
 If so, what meds/supplements? ________________________________________ 
10. Take NSAIDS (such as aspirin, ibuprofen, or advil) fairly consistently      Yes       No 
11. Smoker     Yes  No 
12. Wt stable for 6 months    Yes  No 
13. Exercise more than 3 hrs/wk?  Yes  No 
14. Plan to lose wt in the next 12 wks  Yes  No 
15. On cholesterol lowering meds  Yes  No 
16. Do you have high cholesterol (>200 mg/dL)?  Yes               No           Unknown 
 Total-C:_________ LDL-C:_________ HDL-C_________ 
17. Do you have high triglycerides (>150 mg/dL)?  Yes No  Unknown 
18. Liver Disease    Yes  No 
19. Do you have a problem fasting for 8 hrs prior to blood draws? 
      Yes  No 
20. Do you have a problem with drinking tart cherry juice, or a similar beverage, everyday for 
28 days?    Yes  No 
21. Are you already drinking pomegranate juice, cherry juice, or a similar beverage? 
      Yes  No 
22. Do you have a problem with providing venous blood samples from your arm and a saliva 
swab from your mouth?   Yes  No 
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VERBAL SCRIPT/DISCLOSURE STATEMENT 
 
Hello, my name is (Katie Coles). I am a Human Nutrition graduate student at 
Arizona State University Polytechnic campus. I am collecting information for a 
study about the effects of 100% tart cherry juice on chronic disease biomarkers. 
You have been selected for inclusion in this project based on your willingness to 
participate in this study and your consistence with inclusion criteria. 
 
The information I gather here will only be used for this study and will not be 
published or shared with the public. I will only include your name on this 
disclosure statement and thereafter, you will be assigned an unidentifiable code. 
In other words, every effort will be made to protect the confidentiality of the 
information you provide. You are not required to participate in this project. 
 
There will be no benefits for you personally if you participate in this project other 
than the experience. If you do choose to participate, your weight, height, and 
waist circumference will be measured on each of the 4 visits, you will be asked to 
fill out a brief dietary questionnaire once per week and a physical activity log 
daily, and you will be asked to consume 8 oz of tart cherry juice or placebo daily 
for 8 of the 12 weeks of the study. A total of 4 blood draws will be performed; 1 
blood draw at the first visit and then 1 every 4 weeks over the 12-week study 
period. Each visit will last approximately 30 minutes. 
 
Will you be willing to participate in this project? Can you come to ASU Poly? If 
not, would you be willing to visit ASU in Tempe? If at any time during the study 
you wish to stop, please inform me and we will not continue. 
 
Do you understand? Do you have any further questions? 
 
Thank you very much for your time and participation. 
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 CONSENT FORM 
Effects of Tart Cherry Juice on Chronic Disease Biomarkers 
 
INTRODUCTION 
The purposes of this form are to provide you (as a prospective research study participant) 
information that may affect your decision as to whether or not to participate in this research and to 
record the consent of those who agree to be involved in the study. 
RESEARCHERS  
Keith R. Martin, Ph.D., MTox, an Assistant Professor of Nutrition at Arizona State University, 
and Katie Coles, graduate student in the Nutrition Program, have invited your participation in a 
research study. 
STUDY PURPOSE 
The purpose of this research study is to determine if anthocyanin-rich tart cherry juice will affect 
plasma lipid levels and inflammatory marker levels in humans. 
DESCRIPTION OF RESEARCH STUDY 
You have indicated that you are at least 18 years of age, a non-smoker, not pregnant or lactating, 
and have not been diagnosed with diabetes. We are seeking adults who currently have a BMI of at 
least 25.0 kg/m2. You will need to keep your diet and exercise routine the same throughout the 
study. This study will involve 4 visits to either the Health Sciences Center at the ASU Polytechnic 
Campus in Mesa, AZ or the Clinical Research Unit (CRU) in Tempe, AZ following an 8-hour fast. 
You will be asked to complete a brief medical history questionnaire once a week and a physical 
activity log daily. At each visit, height, weight, and waist circumference will be recorded. We will 
also collect a swab of your inner cheeks of your mouth. Visits should last approximately 30 
minutes, and at this time, participants will have their blood drawn and receive 4 weeks of 
beverages to be consumed on a daily basis. If you forget to consume the beverage you will need to 
notify the investigators of the study. If you say YES, then your participation will last for 12 weeks. 
Approximately 30 subjects will be participating in this study. 
RISKS 
You may feel pain at the site of the needle insertion or experience mild bruising and faintness. As 
with any research, there is a possibility of other risks that have not yet been identified. 
BENEFITS 
This study will provide information regarding cherry juice consumption as it relates to 
cardiovascular disease and inflammation within the body. 
NEW INFORMATION 
If the researchers find new information during the study that would reasonably change your 
decision about participating, then they will provide this information to you. 
CONFIDENTIALITY 
All information obtained in this study is strictly confidential unless disclosure is required by law. 
The results of this research study may be used in reports, presentations, and publications, but the 
researchers will not identify you. In order to maintain confidentiality of your records, Dr. Martin 
will utilize subject codes that will be placed on all data obtained. A master copy of the codes will 
be kept in a locked filing cabinet away from all data samples collected. All confidential 
information will be disposed of by shredding or incineration at the termination of the study. 
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WITHDRAWAL PRIVILEGE 
You are permitted to withdraw from the study at any time and for any reason. Deciding to 
withdraw from the study will not affect you in any manner. 
COSTS AND PAYMENTS 
The researchers want our decision about participating in the study to be absolutely voluntary. They 
recognize that your participation may pose some inconvenience (i.e. traveling and time 
commitment). In order to thank you for your time, a $10 gift card will be provided after each 
blood draw (four total draws). 
COMPENSATION FOR ILLNESS AND INJURY 
If you agree to participate in the study, your consent does not waive any of your legal rights. 
However, no funds have been set aside to compensate you in the event of injury. 
VOLUNTARY CONSENT 
Any questions you have concerning the research study or your participation in the study, before or 
after your consent, will be answered by Dr. Martin; 6950 East Williams Field Road, Mesa, 
Arizona 85212 or call at (480) 727-1925. 
 
If you have any questions about your rights as a subject/participant in this research, or if you feel 
you have been placed at risk; you can contact the Chair of the Human Subjects Institutional 
Review Board, through the ASU Office of Research Integrity and Assurance, at 480-965 6788. 
 
This form explains the nature, demands, benefits and any risk of the project. By signing this form 
you agree knowingly to assume any of the risks involved. Remember, your participation is 
voluntarily. You may choose not to participate or to withdraw your consent and discontinue 
participation at any time without penalty or loss of benefit. In signing this consent form, you are 
not waiving any legal claims, rights, or remedies. A copy of this consent form will be given 
(offered) to you. 
 
Your signature below indicates that you consent to participate in the above study. 
 
___________________________    _______________________________  ____________ 
Subject’s Signature                  Printed Name     Date  
  
___________________________    ________________________________ 
Contact Phone Number                  Email  
INVESTIGATOR’S STATEMENT 
“I certify that I have explained to the above individual the nature and purpose, the potential 
benefits and possible risks associated with participation in this research study, have answered any 
questions that have been raised, and have witnessed the above signature. These elements of 
Informed Consent conform to the Assurance given by Arizona State University to the Office for 
Human Research Protections to protect the rights of human subjects. I have provided (offered) the 
subject/participant a copy of this signed consent document.” 
 
Signature of Investigator ___________________________  Date _____________ 
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Medical History Questionnaire 
Age: _______ 
Gender (circle one):  M F 
Ethnicity (please circle): Hispanic or Latino          Not Hispanic or Latino 
Race: (please circle):  American Indian/Alaska Native        African-American       White 
Native Hawaiian/Other       Pacific Islander       Asian          Other 
 
1. Do you regularly take prescribed and/or over-the-counter medications or dietary 
supplements?    Yes  No 
If yes please list: 
Medication/ 
Supplements 
Frequency Reason and duration 
   
   
   
   
   
 
2. Have you ever been diagnosed with any of the following conditions? 
Diabetes      Yes   N o 
Thyroid problems     Yes   No 
Kidney disease      Yes   No 
Cancer       Yes   No 
Liver disease      Yes   No 
Atherosclerosis      Yes   No 
Rheumatoid arthritis     Yes   No 
High cholesterol     Yes   No 
High blood pressure     Yes   No 
Gastrointestinal problems    Yes   No 
Other illness(es): _______________________________________________________ 
  
Participant ID#: __________ 
Date: ___________________ 
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             8 oz cherry juice daily  Washout          8 oz cherry juice daily 
                   Period   
        









Blood Draw 1       Blood Draw 2         Blood Draw 3      Blood Draw 4 
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 Anthocyanin-rich foods and beverages to avoid during the 7-week Cherry 
Study being conducted at the ASU Nutrition Department 
 
 
• Red grapes and juice 
• Pomegranates and juice 
• Berries such as blueberries, cranberries, raspberries, strawberries, 
blackberries, and Acai berries and juices 
• Egg plant 
• Red cabbage 
• Red wine 
• Dark chocolate 
























If there are questions, please contact: 
 
Katie Coles 
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24-HOUR FOOD RECORD 
  



















































Participant ID #: __________ 
Date: ___________________ 
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INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
 
We are interested in finding out about the kinds of physical activities that people do 
as part of their everyday lives.  The questions will ask you about the time you spent 
being physically active in the last 7 days.  Please answer each question even if you 
do not consider yourself to be an active person.  Please think about the activities you 
do at work, as part of your house and yard work, to get from place to place, and in 
your spare time for recreation, exercise or sport. 
 
Think about all the vigorous activities that you did in the last 7 days.  Vigorous 
physical activities refer to activities that take hard physical effort and make you 
breathe much harder than normal.  Think only about those physical activities that you 
did for at least 10 minutes at a time. 
 
1. During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, digging, aerobics, or fast bicycling?  
 
_____ days per week  
 
   No vigorous physical activities   Skip to question 3 
 
 
2. How much time did you usually spend doing vigorous physical activities on 
one of those days? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
Think about all the moderate activities that you did in the last 7 days.  Moderate 
activities refer to activities that take moderate physical effort and make you breathe 
somewhat harder than normal.  Think only about those physical activities that you did 
for at least 10 minutes at a time. 
 
3. During the last 7 days, on how many days did you do moderate physical 
activities like carrying light loads, bicycling at a regular pace, or doubles 
tennis?  Do not include walking. 
 
_____ days per week 
 
   No moderate physical activities  Skip to question 5 
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4. How much time did you usually spend doing moderate physical activities on 
one of those days? 
 
_____ hours per day 
_____ minutes per day 
 
  Don’t know/Not sure  
 
 
Think about the time you spent walking in the last 7 days.  This includes at work and 
at home, walking to travel from place to place, and any other walking that you might 
do solely for recreation, sport, exercise, or leisure. 
 
5. During the last 7 days, on how many days did you walk for at least 10 
minutes at a time?   
 
_____ days per week 
  
   No walking     Skip to question 7 
 
 
6. How much time did you usually spend walking on one of those days? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
The last question is about the time you spent sitting on weekdays during the last 7 
days.  Include time spent at work, at home, while doing course work and during 
leisure time.  This may include time spent sitting at a desk, visiting friends, reading, 
or sitting or lying down to watch television. 
 
7. During the last 7 days, how much time did you spend sitting on a week day? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
 
This is the end of the questionnaire, thank you for participating 
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Nutrient composition of 8 fl. oz. of placebo and 100% tart cherry juice 
Nutrient  Placebo 100% tart cherry juice 
Calories, kcal 92.2 106.4 
Carbohydrates, g 23.0 26.6 
Protein, g 0 1 
Fat, g 0 0 
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Placebo Beverage Preparation  
Each subject is to be provided with 8 bottles of prepared Placebo to take home and will 
be instructed to freeze 4 bottles and store the remaining 4 bottles in his or her refrigerator 
to be used per instructions. 
Ingredients: 
• SmartWater (8 bottles per participant) 
• Dextrose 
• Fructose 
• Black Cherry flavored Kool-Aid 
• Lemon Powder 
• McCormick’s Red Food Coloring 
• McCormick’s Blue Food Coloring 
Procedure: 
1. Pour 3 bottles SmartWater into gallon pitcher. 
2. Weigh 145g dextrose into food weigh boat. Add to pitcher. 
3. Weigh 145g fructose into food weigh boat. Add to pitcher. 
4. Measure ½ teaspoon red food coloring. Add to pitcher. 
5. Add 6 drops blue food coloring.  
6. Add 3 packets black cherry flavored Kool-Aid. 
7. Add 3 packets lemon powder. 
8. Stir to mix well. 
9. Use funnel to add 28oz. prepared tart cherry juice into each of the bottles. 
10. Cap and clean bottles.  
11. Store in freezer. 
12. Provide 8 bottles of prepared placebo to subject. 
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Weight: ________________   Blood Pressure: ________ 
Height: _________________   Pulse: ________________ 
Calculated BMI: __________   Sed. Rate: _____________ 




Weight: ________________   Blood Pressure: ________ 
Height: _________________   Pulse: ________________ 
Calculated BMI: __________   Sed. Rate: _____________ 




Weight: ________________   Blood Pressure: ________ 
Height: _________________   Pulse: ________________ 
Calculated BMI: __________   Sed. Rate: _____________ 




Weight: ________________   Blood Pressure: ________ 
Height: _________________   Pulse: ________________ 
Calculated BMI: __________   Sed. Rate: _____________ 
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Procedure for Westergren Method 
Adapted from Thermo Fisher Scientific 
 
1. Shake filling reservoir downward to force pre-loaded saline to the bottom 
of the reservoir. Keep upright and remove reservoir cap. 
 
2. Add 1 mL EDTA-treated whole blood to the level of the filling line. 
3. Replace cap. 
4. Mix the saline and EDTA-treated whole blood by performing a minimum 
of 8 inversions. 
 
5. While holding the reservoir with one hand, hold the Dispette tube at the 
180mm mark with the other hand and penetrate the cap membrane. 
 
6. Continue to insert the Dispette tube until it reaches the bottom of the 
reservoir. The blood should rise up the Dispette tube until it reaches or 
surpasses the grommet at the zero level. 
 
7. Place the full Dispette assembly in a stand and ensure that the tube is at 90 
degrees ± one degree to the horizontal. 
 
8. Record the blood level in millimeters following one hour of sitting. 
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Single Analyte ELISA Procedure 
Adapted from SABiosciences Corporation 
 
 
The Single ELISArray Kits measure the amount of an individual chemokine or 
cytokine using an ELISA, and each 96-well plate is coated with a protein-specific 
capture antibody. Therefore, the same general measurement technique is used to 





1. Prepare your experimental samples and replicate serial dilutions of the Antigen 
Standard. 
2. Pipette 50 µL of Assay Buffer into each well. 
3. Transfer 50 µL of standards and/or samples to the appropriate wells of the ELISA 
strips. 
4. Gently shake plate for 10 seconds and incubate for 2 hours at room temperature. 
5. Wash the ELISA wells: 
a. Decant well contents and add 350 µl × Washing Buffer. 
b. Gently shake plate for 10 seconds and decant. 
c. Blot array upside down on absorbent paper to remove any remaining 
buffer. 
d. Repeat wash 2 more times. 
6. Pipette 100 µL of Detection Antibody solution and incubate for 1 hour at room 
temperature. 
7. Wash ELISA wells as previously described. 
8. Pipette 100 µL Avidin-HRP solution to wells. Incubate for 30 minutes in the dark 
at room temperature. 
9. Wash ELISA wells 4 more times. 
10. Add 100 µL of Development Solution to each well and incubate the plate for 15 
minutes in the dark at room temperature. 
11. Add 100 µL of Stop Solution to each well. The color should change from blue to 
yellow. 
12. Read the absorbance at 450 nm within 30 minutes of terminating the reaction. 
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